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ABSTRACTS 
Chapter I 
This chapter presents a general introduction to the 
cellular metabolism of calcium with particular reference 
to the concept of calcium pools. The importance of the 
ionized calcium pool of the cytosol in determining the 
specific function of cells and tissues is discussed. 
A model for stimulus-release coupling in mast cells 
is presented. Excitation-contraction (EC) coupling in 
skeletal muscle is defined and the fundamental premises 
required for a theory on EC coupling are given. The two 
basic theories of excitation-contraction coupling are 
briefly reviewed. 
Chapter II 
We have discovered a new class of drugs which induce 
the release of 3H-serotonin in mast cells. Verapamil, 
previously described as a "specific calcium antagonist", 
was found to release 3H-serotonin from mast cells. Our 
study investigated and compared verapamil and compound 48/80, 
a drug previously known to be a potent degranulator of 
mast cells. 
This investigation revealed that low concentrations 
3 
of verapamil inhibited the spontaneous release of H-
-v-
serotonin and efflux of 86Rb+ in mast cells. High concen-
tration of veraparnil caused an increase in the rate of 
3 86 + the release of H-serotonin and Rb from mast cells. 
Compound 48/80 causes only an increase in the release 
3 86 + 
of H-serotonin and Rb -efflux. The effect of compound 
48/80 and verapamil on the rate of 86Rb+-efflux in mast 
cells was investigated. 
The significance of these results is discussed. 
Verapamil, at low concentrations, is thought to act as 
a "specific Ca channel blocker 11 • The increase in 86Rb+ 
efflux from mast cells induced by high concentration of 
verapamil suggests an increase in concentration of 
. c ++ cytosol1c a . The mobilization of calcium into the 
cytosolic pool is believed also to trigger the release 
of 3H-serotonin from the mast cell. We propose that 
verapamil is not simply a calcium antagonist in mast cells 
but also has the ability at higher concentrations to 
cause an increase in ionic or cytosolic Ca2 +. 
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Chapter III 
A comparative study of the effects of compound 48/80, 
verapamil, and newly synthesized derivative of verapamil 
called "crosslinked verapamil" on mast cells has been 
undertaken with the goal to identify the cellular site 
of action of the drugs. We have studied the role of 
crosslinking in the mechanism of action of compound 48/80 
and verapamil. Analogies are drawn to our study of the 
interaction of crosslinked antigen with immunoglobulin E 
bringing about the degranulation of mast cells. Cross-
linked verapamil was found to be more potent in 
causing the release of 3H-serotonin from mast cells. 
Pretreatment of mast cells with neuraminidase was 
found to inhibit the r~lease of 3H-serotonin caused by 
compound 48/80 but does not change the release of 3H-
serotonin caused by verapamil and crosslinked verapamil. 
We propose that compound 48/80 interacts with components 
of the cell surface that contain negatively charged 
sialic acids. In contrast, verapamil and crosslinked 
verapamil could operate intracellularly or at cell mem-
brane sites that are not affected by pretreatment of the 
mast cell with neuraminidase. 
We also examined possible mechanisms for the degranu-
lation of mast cells by verapamil and discussed the 
kinetics of 3H-serotonin release from mast cells caused 
by compound 48/80, crosslinked verapamil and verapamil. 
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Chapter IV 
The nature of a contracture in skeletal muscle caused 
by compound 48/80, a potent agent of degranulation of 
mast cells, was investigated. The observation that the 
contracture was inhibited by pretreatment of the muscle 
indicated that compound 48/80 interacts with cell surface 
structures that contain neuraminidase-sensitive sialic 
acids essential for activity. An increase in myoplasmic 
[Ca++] during contracture caused by compound 48/80 was 
suggested by the observation that the rate of 86Rb+-
efflux and the rate of protein degradation are increased 
when the muscle is challenged by the drug. Measurements 
of 45ca uptake during pharmacological challenge of 
the muscle indicated that the increase in the influx 
++ 
of extracellular Ca caused by compound 48/80 was not 
correlated with contracture, i.e., the increase in 45ca 
uptake still occurred in muscle pretreated with neura-
minidase but unable to undergo contracture when challenged 
with compound 48/80. This finding and the observation 
that contracture could occur in the absence of extracellular 
calcium indicated that the extracellular medium was not 
the source of Ca++ required to cause the increase in 
myoplasmic [Ca++] sufficient to activate the contractile 
apparatus. 
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A contracture of skeletal muscle caused by verapamil 
was also investigated by examining dose-dependent 86Rb+-
efflux. This study revealed that verapamil could be 
mobilizing intramuscular pools of calcium in analogy 
to its effects on mast cells to cause contracture. 
A mechanistic model consistent with the experimental 
results is proposed to explain contracture and increased 
45 Ca uptake caused by compound 48/80 and tests of the 
model are offered. Parallels between stimulus-secretion 
coupling in mast cells and stimulus-contracture coupling 
in skeletal muscle are summarized. 
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ABBREVIATIONS 
ATP adenosine triphosphate 
DMEM 
EC 
EDTA 
EGTA 
IgE 
MCB 
PAB 
PBS 
PC 
PCA 
PE 
PS 
SAM 
SR 
t-tubule 
TCA 
Dulbecco's modified Eagles' medium 
excitation-contraction 
ethylenediamine tetraacetic acid 
ethyleneglyco-bis(S-aminoethyl ether) 
N,N'-tetraacetic acid 
immunoglobulin E 
mast cell buffer (Materials and Methods, 
Chapter II) 
protein anabolism buffer (Materials and 
Methods, Chapter IV) 
phosphate buffered saline 
phosphatidyl choline 
passive cutaneous anaphylaxis 
phosphatidyl ethanolamine 
phosphatidyl serine 
S-adenosyl methionine 
sarcoplasmic reticulum 
transverse tubule 
trichloracetic acid 
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CHAPTER I 
BACKGROUND 
2 
A multicellular organism requires specialization of 
cellular function which in turn mandates communication 
between the various types of cells such that the organism 
can generate an integrated response to environmental 
change. A common mechanism of cellular communication 
involves the interaction of an extracellular messenger 
with specific cellular receptors causing the release of 
intracellular secondary messengers, thereby triggering 
the cellular response. An example of an integrated re-
sponse that illustrates these points is the immediate 
hypersensitivity reaction to antigen. An antigen which 
binds to a complex of immunoglobulin E and a specific 
IgE-receptor on the mast cell membrane (Metzger, 1977) 
triggers a change in calcium permeability in the mast 
cell membrane. This causes a transient rise in the con-
centration of calcium, a secondary messenger, in the 
f h 1 Th 1 . Ca++ . cytosol o t e mast eel . e cytoso ic triggers 
a series of biochemical events that lead to the degranu-
lation and subsequent release of biogenic amines and 
chemotactic factors from the cell (Hirata and Axelrod, 
1980). In turn the biogenic amines and chemotactic 
factors continue the integrated response of immediate 
hypersensitivity by specifically interacting with other 
target cells and tissues. For example, histamine 
interacts with target cells of the peripheral 
3 
vasculature causing vasodilation and increased fluid 
permeability across the vascular epithelium (Middleton, 
1980). Again, these final events of immediate hyper-
sensitivity depend on the interaction of an extracellu-
lar messenger, histamine, with a specific cellular re-
ceptor which in turn leads to the tissue or cellular 
response. 
The interaction of extracellular messengers with 
specific cell surface receptors causing the generation 
of intracellular secondary messengers has two basic 
mechanisms. The receptor, such as the IgE receptor 
(Metzger, 1979),could be at the cell surface and serve 
via induction of changes in structure and enzymatic 
activity in the membrane as a generator of intracellular 
secondary messenger or the intracellular messenger could 
be transported directly into the cytoplasm, such as the 
steroid-receptor complex (Bischoff and Bryson , 1977), to 
interact with target structures to cause the cellular 
response. Regardless of the site of action of the 
extracellular messenger the induction of intracellular 
secondary messengers or even tertiary messengers are 
central features which, depending on the differentiated 
cell type, initiate or modulate the particular cellular 
response. 
4 
Calcium ions have been implicated as secondary and 
tertiary messengers in the cellular response to the extra 
cellular signals in a large number of systems. The mes-
senger function of calcium occurs within the framework 
of the highly complex cellular metabolism of calcium. 
A useful model for understanding the cellular meta-
bolism of calcium involves the concept of calcium pools. 
The principal pools of calcium of the "typical" cell are 
extracellular calcium, calcium bound to the plasma 
membrane, intramitochondrial calcium, calcium within the 
endoplasmicreticulum, bound calcium in the cytosol and 
free ionized calcium in the cytosol. The distribution 
of calcium in these pools is partially determined by the 
permeability of calcium across the plasma membrane, 
the mitochondrial membrane and the membrane of the endo-
plasmic reticulum. Also the, ATP-dependent calcium pumps in 
these membranes play an important role in determining the 
distribution of calcium in the cellular pools. In muscle 
the highly specialized sarcoplasmic reticulum determines 
to a large extent the transient distribution of calcium 
in this tissue. 
A cellular response that involves messenger calcium 
is usually correlated with a change in the concentration 
of free ionized calcium in the cytosol. For example, 
a transient increase in the free myoplasmic calcium con-
5 
centration from 0.1 µM to 1-2 µM is seen in the excitation-
contraction cycles of skeletal muscle (Caputo, 1978). 
The principal source of the messenger calcium in muscle 
is the sarcoplamsic reticulum and the target of the mes-
senger is the regulatory troponin of the actin-myosin 
contractile apparatus. The contractile response is 
++ terminated by the removal of the messenger Ca from 
the myoplasm by the ATP-dependent pumps of the sarco-
plasmic reticulum (Hasselbach, 1980). A partial list of 
cellular events that are known to be initiated or modu-
lated by changes in the concentration of calcium in the 
important cytosolic pool are given in Table I. 
Table I, Chapter I - Cellular Events Initiated of Modulated by 
Changes in Cytosolic [Ca++] 
Tissue 
Red cell 
Salivary gland 
Lacrimal gland 
Exocrive pancreas 
Liver cell 
Gastrointestinal 
epithelium 
Adipocytes 
Neutrophils 
Neurons 
Mast cells 
Renal cells 
Protozoa 
Pancreatic B-cells 
Egg cell 
Effect 
+ K -efflux 
differential ion flux 
and fluid transport 
differential ion flux 
and fluid transport 
enzyme release 
a-adrenergia glucose 
release 
electrolyte and water 
exchange 
a-adrenergie activation 
Reference 
Gardos (1958) 
Douglas and Poisner 
(1963) 
Parod and Putney 
(1978) 
Case (1978) 
De Wulf and Keppens 
(1976) 
Frizzell (1977) 
Perry and Hales (1970) 
chemotactic and secretory Naccache et al (1977) 
responses 
transmitter release 
IgE-induced degranulation 
gluconeogenesis 
ciliary motility 
secretion of insulin 
activation 
Rahamimoff et al (1978) 
Hirata and Axelrod (1980) 
Nagata and Rasmussen (1970) 
Schmidt and Eckert (1976) 
Malaisse et al ( 1976) 
Okamota et al (1976) 
CJ) 
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Introduction to Mast Cells 
Mast cells are granulocytes found in the connective 
tissue and are characterized by staining with basic dyes 
(Ehrlich, 1879). Acid mucopolysaccharides, such as 
heparin, account for the metachromasia of the granules. 
The mast cell is closely related to the blood-borne 
basophil. The basophil is round and regular in cell shape, 
contains a multilobed nucleus similar to other granu-
locytes and has relatively few granules. The mast cell 
has irregular cell shapes, has a round nucleus and has 
numerous delicate granules. The granules of both cells 
contain histamine and serotonin stored as an amine-protein 
heparin complex (Bergendorff and Uvnas, 1972). 
The triggering of the mast cell is the focal point 
of immediate hypersensitivity. Mast cells when activated 
release the contents of their granules in a process 
called degranulation. The granules contain mediators 
which precipitate either a localized inflammatory re-
action or a severe systemic reaction called anaphylactic 
shock. Mediators, such as histamine, cause the relaxa-
tion of smooth muscle of the local vasculature and cause 
fluid leakage into the surrounding tissue. Also, mast 
cells release chemotactic factors which attract other 
leukocytes and enzymes that degrade local tissue, further-
ing the inflammatory response and possibly laying the 
groundwork for any subsequent repair. 
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Allergic responses are triggered by allergens inter-
acting with immunoglobulin E bound to the surface of mast 
cells. Because allergies serve no obvious function, there 
is considerable debate on what actually is the evolutionary 
benefit of the mast cell. Kay (1979) believes that the 
mast cell plays a key role in protection from parasites. 
Specifically mast cells were shown to degranulate in the 
presence of IgE specific for shistosomula. The mast 
cells release a chemotactic factor (ECFA) which attracts 
eosinophils. Kay (1979) found the eosinophils could cause 
the death of theshistosomula if the parasites were pre-
coated with IgG and the C3 component of the complement. 
Many correlations have been found between parasitic 
infections and IgE. For example, a role for IgE and the 
mast cells in protection from parasites was inferred 
in the study of Grove and Forbes (1975) which showed that 
individuals with increased levels of blood-borne IgE 
have an increased resistance to hookworm infestation. 
While the function of the mast cell is not clear, 
much progress has been made on resolving the mechanism 
of degranulation. Hirata and Axelrod (1980) proposed 
a mechanism for the IgE-mediated release of histamine from 
mast cells that tied together many past observations ondegranu-
lation. For example, Hirata and Axelrod (1980) found that 
Rocr2 
ROCH2 
phosph~tidyl~ 
serine 'If 
/R 
CH20-f-OCH2CH2NH2 
(PS) co2 0-
phosphatidylethanolamine 
(PE) 
PMT I 
SAM 
ROClI2 
ROCH2 I R 
~ Clf2 -0P-OCH2CH2 NCH3 
• H o-
PMT II 
2SAM 
phosphatidyl 
choline 
(PC) 
phosphatidyl N-monomethylethanolamine 
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the central feature in stimulus-secretion coupling in 
mast cells is the enzymatic transfer of methyl groups 
to phospholipids. They demonstrated that an early 
step in the activation of the mast cell was the rapid 
3 incorporation of H-methyl group from S-adenosyl 
methionine (SAM) into the phospholipid fraction of the 
membrane of the mast cell. Degranulation of the mast 
cells and the methyltransferase were inhibited by a specific 
methyltransferase inhibitor (Ishizaka et al, 1980). 
This result explained the long standing observation that 
ROC~2 
ROCH2 
phosph~tidyl~ 
serine ~ 
/R 
CH20-f-OCH2CH2NH2 
(PS) co2 0-
phospbatidylethanolamine 
(PE) 
PME I 
SAM 
PME II 
2SAM 
phosphatidyl 
choline 
(PC) 
phosphatidyl N-monometbylethanolamine 
mast cells required the addition of phosphatidylserine to 
degranulate in the presence of IgE (Keller, 1962). The 
methylation of the phospholipids was correlated with an 
increased influx of 45ca into the mast cells (Ishizaka et 
al, 1980). The increased permeability to calcium was 
thought to be caused by the methylation and subsequent 
flipping of phospholipids of the inner surface of the mem-
brane to outer surface of the membrane which in turn causes 
a decrease in membrane viscosity. The increase in membrane 
10 
fluidity supposedly would allow unknown components of the 
cell surface to aggregate and thus increase Ca++ perme-
ability. Hirata and Axelrod (1980) proposed that the 
influx of calcium activated the Ca-dependent enzyme phos-
pholipase A2 . The activated phospholipase A2 converts 
PC into lysophosphatidylcholine, a substance that pro-
motes calcium-dependent cell fusion (Poole et al, 1970) 
and enhance degranulation of mast cells (Giacobini et al, 
1965). Since the release of histamine involves the fusion 
of membrane enclosed granules with the outer membrane 
(Goth and Johnson, 1975) the production of lysophosphati-
dylcholine and the influx of calcium may be important 
events in the final stages of degranulation. However, 
the mechanism of fusion of granules with the cell surface 
is not known. 
The Hirata and Axelrod (1980) model for IgE-mediated 
release of histamine may not be completely applicable 
to other agents that degranulate mast cells. For example, 
the potent ctegranulating agent, compound 48/80, does not 
strictly require extracellular calcium for its action 
(Uvnas and Thon, 1961). However, the Hirata and Axelrod 
(1980) model which implies that extracellular calcium 
has a role in degranulation, may be valid if compound 
48/80 induces a methylation event that releases calcium 
11 
from some yet undetermined calcium pool. The addition of 
phosphatidylserine is not required for the compound 48/80-
mediated degranulation of mast cells (Goth et al, 1971). 
There is no simple extension of the model of Hirata and 
Axelrod (1980) that would both explain the requirement 
for PS in the degranulation of mast cells by IgE and also 
account for the apparent lack of this requirement in the 
degranulation of mast cells by compound 48/80. Since 
degranulation of mast cells by IgE feature utilization of 
PS in the plasma membrane this particular membrane may 
have a specific requirment for PS. In contrast, the degranu-
lation of mast cells by compound 48/80 does not necessarily 
feature changes in phosphilipid methylation in the plasma 
membrane, but may feature a similar process in the membrane 
defining the intracellular calcium pools. These intra-
cellular calcium pools are thought to be mobilized in the degranu-
lation of mast cells by compound 48/80 (Douglas and 8eda, 
1973) and it is possible that the mast cell does not 
require PS for degranulation by compound 48/80 because 
the membrane of the intracellular calcium pools have suf-
ficient PS for this process. 
12 
Excitation-Contraction Coupling in Skeletal Muscle 
Almost all of the major steps ·in the contractile 
activation of skeletal muscle are now well-established. 
The depolarization of the muscle or muscle fibers at the 
neuromuscular junction is the first step leading to the 
contraction of the muscle. The action potential of a 
cholinergic nerve is correlated with the release of 
vesicles containing the transmitter acetylcholine. The 
acetylcholine interacts with specific receptors at the 
neuromuscular junction (Heidman and Changeaux, 1978) 
including a uniform depolarization of the transmembrane 
resting potential of the muscle. The depolarization is 
basically due to an increased permeability of the muscular 
membrane to sodium ion. A threshold depolarization occurs 
when sufficient transmitter is released at the neuro-
muscular junction. The subsequent action potential spreads 
throughout the muscle via localized changes of ionic con-
ductance. The muscle action potential features a voltage 
and time-dependent increase in Na+ current and a delayed 
voltage and time-dependent increase in potassium conduc-
tance (Adrian et al, 1970). The resting transmembrane 
potential is re-established after the action potential 
+ + by the transport of sodium and potassium by Na /K -
ATPases back across the muscle membrane. 
13 
The inward spread of the activation of the muscle 
from the sarcolemma through the transverse tubule sys-
tem is the second major step in the contractile mechanism 
(Constantin, 1975). The coupling between the muscular 
action potential and contraction could be abolished by 
treatment of the muscle with hypertonic glycerol (Gage 
and Eisenberg, 1969). Anatomical studies of the muscles 
treated with glycerol showed that the t-tubule system 
was physically pinched off from the sarcolemma by the 
glycerol treatment. These experiments implied that 
coupling between excitation and contraction in skeletal 
muscle required a direct communication of the action 
potential of the sarcolemrna into the t-tubule system. 
The third basic step in the sequence for the acti-
vation of the muscle at the neuromuscular junction to the 
activation of the contractile apparatus is the coupling 
between the activation of the t-tubule with the increase 
in calcium permeability of the membrane of the sarco-
plasmic reticulum. Anatomically, the t-tubules and the 
sarcoplasmic reticulum are close and form distinct junc-
tions called the SR-t-tubule triadic junctions (Huxley, 
1971). The t-tubule action potential has been correlated 
with the radial spread of the activation of skeletal 
muscle fibers (Constantin, 1975). Despite the correlation 
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between t-tubule activation and the increase in calcium 
permeability of the membrane of the sarcoplasmic reticulum, 
the molecular mechanism of the coupling of these processes 
is not known. Theories proposed to explain this step 
in excitation-contraction coupling will be discussed in 
detail later in this chapter because of their importance 
to the work reported in this thesis. 
The final basic step in the contractile sequence is 
the release of calcium from the sarcoplasmic reticulum 
into the myoplasm causing the activation of the contractile 
apparatus. In skeletal muscle, the myoplasmic calcium 
interacts with a target protein called troponin-C associated 
with the actin-myosin contractile apparatus; binding of 
ca2 + activates an actinomyosin ATPase. The hydrolysis of 
ATP by the actinomyosin ATPase provides the driving energy 
for the interdigitation and "sliding" of the actin and 
myosin filaments during the active shortening of muscle 
(Katz, 1966). The myoplasmic concentration of free cal-
cium is lowered to the resting level ~Y the action of the 
ATP-dependent calcium pumps of the sarcaoplasmic reticulum 
Hasselbach, 1980). This process causes relaxation of 
the contractile apparatus and reduces the tension of 
the muscle to the resting state. 
The calcium binding protein calmodulin (Cheung, 1971) 
is known to directly potentiatethe reuptake of calcium 
into cardiosarcoplasmic reticulum (Katz and Reintulla, 
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1978; Lopaschuk et al, 1980). Calmodulin may also in-
directly cause a cAMP-dependent increase in sarcoplasmic 
reticuluar Ca++ transport by stimulating cardiac 
adenylate cyclase activity (Tada and Kirchberger, 1978). 
However, the role of calmodulin in the relaxation of 
skeletal muscle is not known. 
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Excitation-Contraction Coupling Theories: The Coupling 
Between the t-tubules and the Sarcoplasmic Reticulum 
Several theories have been proposed to explain the 
communication between the t-tubules and the sarcoplasmic 
reticulum. An early approach was to assume that the 
currents in the t-tubule system were transmitted directly 
to the sarcoplasmic reticulum causing a depolarization of 
the sarcoplasmic reticulum, thus leading to the increase 
in calcium permeability. Several studies have shown 
that insufficient ionic current flows through the SR-
t-tubule junction to produce a significant depolarization 
of the sarcoplasmic reticulum (Chandler et al, 1975). 
Another early approach featured extracellular calcium 
ions entering the muscle fiber during the action potential 
and subsequently initiating the contractile response 
(Frank, 1957; Bianchi and Shanes, 1959). But it was 
found that the influx of extracellular calcium during a 
single contraction was insufficient to account for the 
increase in myoplasmic concentration of calcium associated 
with the contractile event. Therefore, to account for 
this discrepancy it was proposed that the small amounts 
of calcium entering the muscle triggered an intracellular 
event that would lead to contraction. This mechanism 
is called the "trigger Ca++" hypothesis of excitation-
contraction coupling (Bianchi, 1968). 
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Several experiments have shown that the intracellular 
event that is triggered by calcium was the release of 
calcium by the sarcoplasmic reticulum. Direct applica-
tion of calcium buffers to skinned skeletal muscle fibers 
induces the release of calcium by the SR (Endo et al, 
1970). A relatively small increase in the concentration 
of Ca++ can cause a rapid release of calcium from 
vesicles derived from the sarcoplasmic reticulum (Kupsaw 
et al, 1980). These two pieces of evidence, repeated 
in other studies, are essential for support of a mechanism 
of direct coupling between calcium and calcium release 
from the sarcoplasmic reticulum of skeletal muscle. 
Despite the accumulating evidence that the "trigger-
Ca++,, hypothesis has value in explaining the coupling 
between activation of the t-tubules and release of calcium 
from the SR, the mechanism of the coupling is unknown. 
For example, the calcium pool that provides the "trigger-
++ f h l' . k 1 h h t 11 1 Ca " or t e coup ing is not nown, a t oug ex race u ar 
calcium and calcium bound to the membranes of the t-tubules 
have been suggested (Frank, 1979). There is no conclusive 
evidence pertaining to the molecular mechanism or even the 
molecules involved other than Ca++ in the coupling between 
activation of thet-tubules and the release of calcium. The 
mechanism of excitation-coupling remains one of the major 
ongoing problems in muscle physiology. 
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CHAPTER II 
VERAPAMIL; A NEW AGENT FOR 
ACTIVATION OF MAST CELLS 
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INTRODUCTION 
Verapamil 
The structure of verapamil and its methoxy-derivative, 
D-600 are given below. 
OCH3 CH30 OCH3 CH3 
Veraparnil D-600 
H3C H3C 
H C::N H C::N 
H3C H3C 
CH2 CH 
I I 2 
?H2 CH2 I 
CHz I 
CH2 1-
N-CH N-CH 3 I 3 I 
CH2 
CH2 
I I 
·cH2 ~H. QOCH3 
OCH3 
OCH3 
Verapamil and D-600 were found to be highly potent 
inhibitors of excitation-contraction coupling in the 
mammalian myocardium(Fleckenstein, 1964) and of excitation-
contraction coupling in uterine smooth muscle (Fleckenstein 
and Grun, 1969). The effects on muscle could be overcome 
by increased extracellular Ca++, therefore these drugs 
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were designated as calcium antagonists. Since the dis-
covery of verapamil and D-600 as calcium antagonists in 
heart muscles a large number of systems have been investi-
gated. An incomplete list partially compiled from 
Rosenberger and Triggle (1978) is given in Table II. 
The first general mechanism proposed for the pharma-
cology of verapamil was by Fleckenstein (Kohlhart et al, 
1972), who noted that verapamil did not affect the action 
potential of mammalian cardiac fibers. The cardiac action 
potential is primarily due to an influx of Na ions through 
what is designated as a fast channel. However, verapamil 
did inhibit cardiac contraction and the transient calcium 
current associated with depolarizing membrane potentials. 
Calcium was found to enter the heart through the fast Na-
channel and through its own specific Ca-channel (Mascher 
and Peper, 1969, Reuter, 1967). This flux of calcium 
through the slow Ca-channel was blocked by 
verapamil. Fleckenstein (1977) designated verapamil and 
D-600 as specific Ca-channel antagonists because of these 
findings. Sympathetic 6-receptor stimulating agents such 
as epinephrine andisoproterenol had an opposite effect 
by causing an increase in the Ca current across the cardiac 
membrane (Reuter, 1965). 
Verapamil has been shown effective in a variety of 
therapeutic situations. For example, the drug has been used as 
Table II,Chapter II - Effects of Verapamil (or D-600) on Cellular Function 
Tissue 
Aorta 
Portal vein 
Ear artery 
Ileum 
Pancreatic 
islets 
Action 
relaxation of norepinephrine (NE) 
effect 
decreases spontaneous contractions 
relaxation of NE effect 
relaxation of acetylcholine effect 
inhibition of insulin release 
Neurohypophysis inhibition of mytocin release 
Pituitary inhibition of ACTH release 
Adrenal inhibition of catacholamine release 
Pulminary relaxation of K+ stimulation 
Artery 
Mesenteric vein relaxation of NE effect 
Reference 
Schuman et al (1975) 
Golenhofen and Herstein 
(1975) 
Golenhofen and Weston 
(1976) 
Triggle et al (1975) 
Malaisse et al, (1976) 
Dreifus et al, (1975) 
Eto et al (1974) 
Pinto and Trifaro (1976) 
Haeusler (1972) 
Church and Zsoter (1980) 
l\J 
CJ1 
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a depressor of a variety of hyperkinetic cardiac phenomena 
by virtue of its excitation-contraction decoupling properties 
on cardiac muscle. Moreover, verapamil has immediate 
positive effects on cardiac arrhythmias (Shamroth et al, 
1972). Verapamil has also been used as a long term thera-
peutic agent. For example, Sandler et al (1968) in a control-
led clinical trial found that verapamil caused a decrease in 
the frequency of angina pectoris in cardiac patients. Vera-
pamil has also been suggested as a possible drug for the 
management of hypertension. The hypotensive action of 
verapamil, at doses below that required for reduction 
of cardiac output, has been proposed to be due strictly 
to changes in peripheral vasodilation (Ross and Jorgensen, 
1967). 
Recently in the popular press, verapamil has been de-
scribed as a potential "wonder drug" in the treatment of 
hypertension (Clark and Shapiro, 1981). A possible 
mechanism for the hypotensive effect of verapamil is 
given in this study. 
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Compound 48/80 
Compound 48/80 was first synthesized by Baltzby et 
al (1949). The compound was prepared by an acid catalyzed 
polymerization of p-methoxyphenethylmethylamine with 
formalin. Morrison et al (1974) radiolabeled the "com-
pound" with 125 1 and found a very broad peak in gel 
filtration of approximately 800 molecular weight. Several 
factors probably contribute to the complexity of the 
mixture. One factor is the formation of isoquinolines 
as a side reaction. 
¢ CH3 ~ H'"H H+ 
0CH3 
Isoquinolines do not account for the potent ability of 
compound 48/80 to reduce blood pressure in dogs (Baltzby 
et al, 1949). When tertiary amines were polymerized 
the hypotensive activity was of maximum potency. Because 
tertiary amines do not form isoquinoline derivatives 
Baltzby et al (1949) proposed that the following structure 
was the active ingredient in mixtures of polymerized 
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methoxyphenalkyamines. Another factor possibly contributing 
to the complexity of the compound 48/80 preparation is the 
possibility that the isoquinoline units are crosslinked 
(Evans, 1981, personal communication). 
The ability of compound 48/80 to lower blood pressure 
is probably due to its ability to release histamine from 
tissue mast cells (Mongar and Schild, 1952). 
The release of histamine was due to compound 48/80 causing 
a degranulation of mast cells and basophils. Compound 48/80 
can cause the release of histamines from mast cells in 
the absence of extracellular calcium (Uvnas and Thon, 1961). 
Mast cells when treated with 2 mM EDTA for three hours 
do lose their ability to respond to compound 48/80 
(Douglas and Ueda, 1973). Douglas and Ueda (1973) suggested 
that the EDTA treatment of mast cells caused a depletion 
of the intracellular pools of calcium that are mobilized 
when the mast cells are challenged by compound 48/80. 
In contrast, the degranulation of mast cells caused by 
complexes of IgE and antigen have an absolute requirement 
for extracellular calcium (Ishizaka et al, 1979). 
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Stimulus-Permeability Coupling 
Gardos (1958) found that treatment of red cells 
with EDTA causes a decrease in the possible leakage of 
potassium from red cells. Whitman (1968) later pro-
posed that the decrease in potassium permeability was 
due to a decrease in the concentration of ionized calcium 
in the red cell. Lew and Ferreira ( 1978) showed that 
treatment of red cells with the calcium specific ionophore 
A23187 caused an increase in potassium permeability. 
This they ascribed to the activation of a Ca-sensitive 
potassium channel by the inward movement of extracellular 
calcium. The mechanism for the activation of such 
"channels" is unknown (Putney, 1979). 
The Ca-dependent changes in potassium efflux have 
been observed in a wide variety of cells and tissues 
since the discovery of the "Gardos effect" (Putney, 1979). 
Putney (1979) has coined the term stimulus-permeability 
coupling to describe this effect. Examples of systems 
that exhibit stimulus-permeability coupling are activation 
of salivary glands, stimulation of lymphocytes, hormone 
action on liver cells, and contraction of smooth muscle 
such as the ileum. This study has found that efflux 
of rubidium-86 (an analogue of potassium (Putney, 1979)) 
in skeletal muscle and mast cells was sensitive to 
challenges by verapamil and compound 48/80. 
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MATERIALS AND METHODS 
Isolation of Rat Peritoneal Mast Cells 
The house bred ratsused in this study were predominantly 
of the Fisher-344 breed and occasionally of the Wister-
Furth breed. No differences were observed between the 
breeds in cell yields and cell responses. Rats between 
150 and 300 grams were sacrificed by cervical dislocation 
with a blunt guillotine. The rats were injected in the 
peritoneal cavity with either phosphate buffer saline 
(PBS) or sterile mast cell buffer (MCB). MCB contained 
137 mM NaCl, 2.6 mM KCl, 1.0 mM MgC1 2 , 10 mM Tris (hydro-
methyl)aminomethane, 1 mg/ml bovine-serum albumin 
and 1 mg/ml glucose. MCB was titrated to pH 7.4 with 
concentrated HCl. 
This buffer was modified from Cochrane and Douglas 
(1976) but omitted heparin for it was found that heparin 
precipitated compound 48/80. MCB, unless otherwise 
designated, was used in all the pharmacological studies 
on rat peritoneal cells and P815 mastocytoma cells. 
It is very important to note that CaC1 2 is not a component 
of MCB. The CaC1 2 was omitted when it was found that 
the spontaneous release of 3H-serotonin from mast cells 
isolated in the presence of a calcium containing solution 
was approximately two-fold higher than cellw isolated in 
buffer without caclium. Furthermore, rat peritoneal cells 
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isolated in buffers with no calcium were more reactive to the 
various drugs used in this study. There is a possibility that 
++ the presence of Ca during the isolation somewhat desensi-
tizes the mast cells to further 3H-serotonin release. If Ca++ 
was required for a drug challenge of the mast cells, a 
volume of a calcium chloride stock solution was added 
to the MCB until an appropriate final concentration was 
obtained (usually 2.0 mM). Often, but not reproducibly, 
3 this addition of CaC1 2 caused a small release of H-
serotonin from the mast cells. 
The peritoneal cavity of the rats was massaged 
manually to dislodge cells from the inner peritoneal wall. 
The peritoneal cavity was then cut open and the fluid was trans-
ferred to a plastic centrifuge tube using a Pasteur pipette. 
B. L. Aalseth improved the yields of mast cells by devel-
oping a variation of the standard technique. The rat 
peritoneal cavity was widely exposed by forceps. A second 
person then jetted 10 ml of MCB from a syringe (#22 needle) 
onto the exposed surface of the peritoneal cavity. This 
wash was transferred to the centrifuge tube by pipette to 
complete the first stage of the cell isolation. 
A typical yield of leukocytes was 5 x 105 - 106 cells 
per rat of which approximately 50% were identified as mast 
cells. Two methods were used to crudely identify mast cells. 
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Under the light microscope, mast cells underwent a profound 
and quick change (~ 1 minute) when exposed to relatively 
high concentrations of compound 48/80. The mast cell 
visibly degranulated and a characteristic halo of vesicles 
surrounded the cells. Those cells were assumed to be mast 
cells because of their sensitivity to the classical mast 
cell degranulating agent; compound 48/80. A staining 
procedure differentiated mast cells from the other 
leukocytes. The rat peritoneal cells were exposed to 1% 
alcian blue and 3% acetic acid in 0.15 M NaCl. The cells 
were washed by centrifugation and the stain discarded. 
Then the cells were immediately exposed to 0.1% safranin 0 
in 1% acetic acid and 0.15 M NaCl. After five minutes 
the cells were washed and resuspended in saline. This 
preparation demonstrated the stages in mast cell differentia-
tion. Small lymphocyte-like mast cells contain only 
calcium blue-stained granules. Large mature mast cells 
contain safranin-positive heparin granules and thus stain 
pink. Generally, approximately 50-70% of the leukocytes 
(cells not obviously red cells) showed this pink staining. 
Another 5-10% of the leukocytes showed the characteristic 
blue staining of the immature mast cell. 
Purified mast cells used to verify the staining tech-
niques were isolated by the method of Morrison et al 
(1974). Their method used a lXG gravity separation of 
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rat peritoneal cells in a 1.5% BSA solution of buffered 
saline. The procedure was modified by centrifuging the 
syringe at lOOXG for eight minutes. Even with this extra 
g-force the separation was not as good as described by 
Morrison et al (1974) and there was no detectable "mast 
cell" pellet. Nevertheless, this partial isolation 
. 
allowed some verification of the above staining procedure. 
In general mast cells were not isolated from the 
rat peritoneal cell mixture for several expedient reasons. 
Morrison et al (1974) showed that compound 48/80, a 
degranulating agent used in this study, bound exclusively 
to the mast cell population. More important, the assay 
for mast cell amine release involved prepacking of the 
rat peritoneal cells with 3H-serotonin. Morrison et al 
(1974) demonstrated that the serotonin was incorporated 
almost exclusively into mast cells. Furthermore, the 3H-
serotonin behaved the same as the endogeneous histamine. 
The release of 3H-serotoin and histamine was identical 
when measured as a function of dosage of compound 48/80. 
Thus, for practical purposes the mast cells were not 
isolated from the rat peritoneal cell mixture. The terms 
mast cells and rat peritone~lcells are used interchange-
ably in this study because of the exact functional simi-
larities with regards to elicited release of biogenic amines. 
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The second stage of mast cell preparation involved 
the loading of 3H-serotonin into the cells. The cells 
from one to four rats were suspended at room temperature 
in 50 ml of MCB containing approximately 20 µCi of 3H-
serotonin (Amersham). After 1-1.5 hours the cells were 
washed four to five times in 50 ml of PBS or MCB with 
the final suspension always in MCB. These cells were 
aliquoted into 1.5 ml microcentrifuge tubes for subsequent 
preincubations and pharmacological challenges. Double 
label experiments using 86RbCl (Amersham) were accomplished 
by simultaneous loading of cells with~ 30 µCi of 86Rb+ 
along the 3H-serotonin. 
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Measurement of 3H-Serotonin Release in Rat Mast Cells 
In a typical mast cell experiment 1.0 ml of 3H-
serotonin packed cells were aliquoted into plastic micro-
centrifuge tubes. If preincubation was desired a 
small volume of the stock solution (i.e., lOOX CaC1 2 ) 
was first added to the microcentrifuge tube. After 
the preincubation period small volumes of drug or hapten 
stock solutions were added to the tubes. The tubes were then 
shaken and placed in a 37°C shaker-water bath for the 
desired length of time. The tubes were then centrifuged 
at high speed in Eppendorf table top ultracentrifuges 
for three minutes. Aliquots of the supernate were 
transferred to scintillation vials. The 3H-serotonin 
and 86Rb were counted in scintillation fluid with a 
Beckman counter using standard methods. In a procedure 
to determine the maximum possible release of 3H-serotonin, 
several cell samples were not centrifuged. These samples 
were acidified with ~ 25 µ£ of concentrated hydrochloric 
acid and placed in a steam bath for 10-20 minutes. 
Aliquots of the product were counted and the results 
served as the 100% potential release level for 3H-
serotonin in the rat peritoneal cell population. 
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P815 Mastocytoma: Origin and Maintenance 
The P815 mastocytoma was induced in a male DBA/2 mouse 
by repeated exposure to methylcholanthrene (Dunn and 
Potter, 1957). The distinguishing feature of the tumor 
cells were their high degree of granular metachromasia 
when stained by 0.5% ~ toluidine blue. The number of stained 
granules per cell was greatly reduced when compared to 
the normal mast cell. The tumor was first introduced 
to tissue culture by Lundak and Raidt (1973). The cell 
line was obtained from the Salk Institute of Biological 
Studies. 
The P815 mastocytoma cell line was maintained in 
incubators kept at 37°C and 5% co2 /100% H2o. The medium 
was Dulbecco's Modified Eagle Medium (DMEM) supplemented 
with 10% calf serum (GIBCO). Further additions were 
1.2 mg/ml glutamine, 0.3 mM non-essential amino acids 
(GIBCO), 100 µg/ml streptomycin.and 100 units/ml penicillin G. 
Cell counts were determined with standard hemocytometers. 
Verapamil 
The verapamil used in this study was a generous 
gift from Knoll Pharmaceutical Company, Whippany, New Jersey. 
37 
RESULTS 
Results Establishing the General Nature of the Release 
of 3H-Serotonin from Mast Cells 
Four basic criteria were established to show that 
the release of 3H-serotonin from mast cells caused by 
verapamil involved degranulation of mast cells; 1) dose-
dependent release of amines from the cell; 2) morpho-
logical changes similar to those caused by the "classical" 
degranulating agent, compound 48/80; 3) dependence of 
the process on metabolic energy; 4) demonstration that 
the drug did not lyse or kill the cell. The results 
establishing these criteria are described below. 
Verapamil causes a dose-dependent release of 3H-
serotonin from rat mast cells (Figure 1). The 
rat cells were loaded with 3H-serotonin in a method 
very similar to that described by Morrison et al (1974). 
They concluded that the release of 3H-serotonin was 
exactly correlated with the release of histamine, an 
indication that both of these biogenic amines were 
released by the same mechanism upon degranulation of 
the mast cell. Morrison et al (1974) also showed that 
the 3H-serotonin was taken up almost exclusively by 
the mast cells in a mixture of rat peritoneal cells and 
suggested that the 3H-serotonin was bound in the granules 
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of the mast cell to the amine-protein-heparin complex 
described by Bergendorf f and Uvnas ( 1972). 
Mast cells exposed for one hour to high concentra-
tions of verapamil (2 mg/ml) were observed under the 
light microscope to undergo a degranulation reaction simi-
lar to what is seen for mast cells exposed to the 
"classical" degranulation agent, compound 48/80. The 
degranulation of mast cells is dependent on cellular 
levels of ATP (Johanson, 1980). Figure 1 demonstrates 
that release of 3H-serotonin from mast cells by verapamil 
was inhibited by preincubation of the cells in a mixture 
of the metabolic poisons, KCN and 2-deoxyglucose. As a 
positive control, the "classical" degranulating agent 
compound 48/80 was also shown to require metabolic energy 
for the degranulation of mast cells (Figure 2). 
Mast cells exposed for one hour to concentrations of 
verapamil that could induce maximal release of 3H-serotonin 
in five minutes were found to exclude the trypan blue 
viability stain. Less than 2% of the mast cells showed 
staining by the dye indicating that the cells were viable 
and the drug was not releasing 3H-serotonin through non-
specific lysis. 
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Figure 1 
The role of energy metabolism in the release of 
3H-serotonin from rat peritoneal cells challenged 
by verapamil. The metabolically inhibited cells 
(-o-o-) were preincubated in 10 mM 2-deoxyglucose 
and 0.3 mM KCN for one hour and 20 minutes at 
25°c in glucose-free MCB. Normal cells (-•-•-) 
were preincubated in regular MCB in parallel with 
the metabolically inhibited cells. The challenge 
with verapamil was for one hour at 37°C. The 
statistical error was estimated to be 10%. 
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Figure 2 
The role of energy metabolism in the release of 
3H-serotonin from rat peritoneal cells challenged 
with compound 48/80. The metabolically inhibited 
cells (-o-o-) were preincubated in 10 mM 2-deoxy-
glucose and 0.3 mM KCN for 40 minutes at 25°C in 
glucose-free MCB. Normal cells (-•-•-) were pre-
incubated in regular MCB in parallel with the meta-
bolically inhibited cells. The challenge with com-
pound 48/80 was for one hour at 37oc. The statis-
tical error was estimated to be 10%. 
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86Rb+- 3H-Serotonin Double Label Experiments in Mast Cells 
Loading of 86Rb+ and 3H-serotonin into mast cells 
and then subsequently monitoring the release of these 
radioactive substances from the mast cells represents 
a novel experimental method (Figures 3 and 4). The 
results of the double label experiment indicate that 
compound 48/80 causes a dose-dependent increase in the 
86 + initial rate (15 minute challenge) of Rb -efflux and 
release of 3H-serotonin from rat peritoneal cells. (Figure 3) 
The results for rat peritoneal cells challenged with vera-
pamil were somewhat different (Figure 4). Low concen-
trations of verapamil cause a small decrease in the spon-
taneous release of 3H-serotonin and 86Rb+. Whereas high 
concentrations of verapamil caused an increase in the 
3 86 + 
release of H-serotonin and Rb from the mast cells. 
86 + The release of Rb is thought to be proportional 
+ to the release of K from cells (Putney, 1979). However, 
the exact relationship between K+-efflux and 86Rb+-efflux 
has not been established for the mast cell system. 
Compound 48/80 caused a concentration dependent 
increase in the rate of 86Rb+-efflux in P815 mastocytoma 
cells (Figure 5). Unlike normal mast cells (Figure 2), 
relatively high concentrations of compound 48/80 were 
required to cause a significant increase in the rate of 
86Rb+-efflux from the P815 cells. Figure 5 showed 
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there was no difference between the dose-response curves 
for 86Rb+-efflux in P815 cells challenged with compound 
48/80 in the presence of extracellular calcium (2 mM Ca++) 
and in the absence of extracellular calcium (short pre-
incubation in MCB containing 0.1 M EGTA)~ It has been 
shown that 86Rb+-efflux is proportional to the concentra-
tion of cytosolic Ca++ in other cell systems (Putney, 
1979), accordingly we assume that the increase in 86Rb+-
efflux in P815 cells challenged with compound 48/80 like-
wise reflects an increase in the concentration of calcium 
in the cytosolic pool. 
Figure 6 shows a dose-dependent increase in 86 Rb+-
efflux in P815 cells challenged by verapamil. This result 
is very similar to the data from 86Rb+-efflux in P815 
cells challenged with compound 48/80. 
*This short preincubation in 0.1 M EDTA was of short enough 
duration and low enough concentration to not significantly 
deplete the intracellular pools of calcium but insured there 
was complete removal of all extracellular calcium. In con-
trast, preincubation of mast cells in 2 mM EDTA for three 
hours caused mast cells to lose their ability to respond to 
compound 48/80 (Douglas and Ueda, 1973). 
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Figure 3 
Double label experiment measuring the initial 
86 + 3 . 
rates of release of Rb and H-seroton1n from 
rat peritoneal cells challenged with compound 
48/80. The cells were isolated and loaded with 
86Rb+ and 3H-serotonin by the methods described 
in Materials and Methods, Chapter II. The 
challenge with compound 48/80 was for 15 minutes 
at 37°C in MCB. 3 The spontaneous release of H-
serotonin (---0---0---) was 795 ~ 70 cpm and the 
maximum possible release was 17,100 ~ 500 cpm. 
86 + The spontaneous release of Rb (-•-•-•-•-) was 
404 + 18 cpm and the maximum possible release was 
795 + 25 cpm. The standard deviation for the 
blanks and the maximum possible release determine 
the ranges of the statistical error in this experi-
ment. 
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Figure 4 
Double label experiment measuring the initial 
rates of release of 86Rb+ and 3H-serotonin 
from rat peritoneal cells challenged with vera-
pamil. The details of this experiment are 
described in Figure 3. The table below in-
eludes standard deviations for the counts of 
the blank and maximum possible release. 
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Figure 5 
The release of 86Rb+ from P815 Mastocytoma cells 
challenged by compound 48/80. The mastocytoma 
cells were suspended in a 2 µCi/ml 86RbC1 2 of 
MCB for 37oc for two hours. The cells were 
washed five times in Ca-free MCB and divided 
in two. One aliquot was incubated for 30 minutes 
in 2 mM ca++ MCB (-•-•-) and the second aliquot 
was incubated 30 minutes in 0.1 mM EGTA MCB 
(--0---0---). The cells were aliquoted into 
small portions and challenged with compound 
48/80 for 10 minutes. The maximum 86Rb+ count 
for the mastocytoma cells was 2320 cpm. The esti-
mated error of each sample was 10%. 
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Figure 6 
The release of 86Rb+ from P815 mastocytoma cells 
by verapamil. The detailed procedure for 
challenging the mastocytoma cells with verapamil 
is described in Figure 5 . The cells were pre-
incuba ted in EGTA (---0---0---) and 2 mM Ca++ 
(-•-•-•-) then challenged with verapamil for 10 
minutes. 
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DISCUSSION 
The Effect of Verapamil on Mast Cells 
The data in Figures 1 and 5 illustrate that vera-
pamil caused the release of 3H-serotonin from rat mast 
cells.This isthe first demonstration that verapamil 
could cause the release of biogenic amines from mast 
cells. 
The discovery that verapamil causes the release of 
3H-serotonin from mast cells is surprising considering 
the previously proposed mechanism of action of the drug 
and what is known about the mechanism of degranulation 
of mast cells. Fleckenstein (1977) proposed that vera-
pamil was a member of the class of drugs that were 
specific "calcium-channel" antagonists. The release of 
histamine from mast cells caused by the classic degranu-
lation agent compound 48/80 is thought to occur by a 
mechanism involving the release of calcium from intra-
cellular pools into the cytosolic calcium pool (Ueda 
and Douglas, 1973). If the release of 3H-serotonin 
from mast cells caused by verapamil is dependent on the 
release of calcium from membrane-bound intracellular 
pools and if the drug can function by blocking intra-
cellular "calcium-channels" of these pools, then verapamil, 
3 itself, would not be expected to cause a release of H-
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serotonin from mast cells. The degranulation of mast 
cells caused by the interaction of antigen and membrane-
bound IgE requires the influx of extracellular calcium 
(Hirata and Axelrod, 1980). If verapmil, 
functions by blocking "calcium-channels" and therefore 
inhibits the influx of extracellular calcium it would not 
be expected to cause the degranulation of mast cells. 
The surprising result that verapamil, itself, causes 
the release of 3H-serotonin from mast cells, therefore, 
casts serious doubt on the proposition that the drug 
is acting strictly as a specific "calcium-channel" 
antagonist as described by Fleckenstein (1977). 
The measurement of 86Rb+-efflux from mast cells was 
an attempt to define a role for cytosolic calcium in the 
mechanism of action of verapamil and compound 48/80. 
Figures 3 and 4 showed that the release of 3H-serotonin 
from mast cells by compound 48/80 and high concentration 
of verapamil occurred with an increase in 86Rb+-efflux 
from the mast cells. In a wide variety of cells and 
· · · th efflux of 86Rb+ ( 1 tissues an increase in e an ana ogue 
of K+) was correlated with an increase in cytosolic Ca++ 
concentrations (Putney, 1979). If this correlation could 
be extended to the mast cell, the release of 3H-serotonin 
by compound 48/80 and high concentrations of verapamil 
would feature an increase in the concentration of cytosolic 
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C ++ a • If indeed the degranulation of the mast cell caused 
by compound 48/80 and high concentrations of verapamil 
features an increase in the concentration of cytosolic 
Ca++ and because the processes occur in the absence of 
extracellular calcium then the drugs could be mobilizing 
calcium from an intracellular pool into the cytosol. 
The data of Figure 4 show a dose-dependent effect of 
verapamil that may be due to the drug acting as a specific 
"calcium-channel" antagonist (Fleckenstein, 1977). Low 
concentrations of verapamil (< 50 µg/l) caused a small 
decrease in both the spontaneous release of SH-serotonin 
86 + 
and the spontaneous efflux of Rb from mast cells. 
If the correlation described by Putney (1979) between 
86Rb+-efflux and the concentration of cytosolic Ca++ is 
valid for mast cells, this decrease in 86Rb+-efflux 
caused by verapamil at low concentrations implies a decrease 
in the concentration of cytosolic Ca++. This slight 
decrease in the spontaneous rate of 86Rb+-efflux is the 
only evidence that could be a consequence of the blocking 
of "calcium-channels" in mast cells. Other effects 
caused by high concentrations of verapamil, such as the 
increased release of SH-serotonin from mast cells, must 
occur while overriding the effects of the proposed block-
age of "calcium-channels" in the mast cells. 
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Compound 48/80 (Figure 5) and verapamil (Figure 6) 
cause a dose-dependent increase in 86Rb+-efflux from 
P815 mastocytoma cells. The P815 cells are thought to 
be similar to immature mast cells and contain fewer g~anules 
relative to the normal mature mast cell (Dunn and Potter, 
1957). The P815 cells do not undergo the morphological 
changes associated with degranulation when exposed to the 
"classical" degranulation agent compound 48/80. Therefore, 
the results of Figures 5 and 6 seem to indicate that 
the increase in 86Rb+-efflux caused by compound 48/80 
and verapamil could occur in "mast cells" that are unable 
to degranulate. If one assumes 86Rb+-efflux is correlated 
. h h t t. f 1. Ca++ (P 1979) wit t e concen ra ion o cytoso ic utney, , 
this result suggests that verapamil can, in fact, mobilize 
intracellular calcium into the cytosolic pool. In P815 
cells, this early step in degranulation does not lead to 
degranulation itself because of a functional defect in 
the cells at some later step in the degranulation pathway. 
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Possible Indirect Effects of Verapamil on Blood Pressure 
Verapamil has been useful in controlling acute and 
chronic hypertension (Zsoter, 1980). We propose that 
a component of the hypotensive effect of verapamil is 
due to the release of vasoactive substances from mast 
cells and basophils. For example, histamine and the slow 
reacting substance of anaphylaxis (SRS-A) are vasoactive 
substances released from mast cells that could lower blood 
pressure. Histamine causes an increase in the leakage of 
fluids from the peripheral vasculature into the connective 
tissue and relaxation of the smooth muscles of the peri-
perhal vasculature both of which can lower blood pressure 
(Middleton, 1980). Also, SRS-A causes an increase in 
peripheral vascular permeability (Lewis and Austen, 1977). 
Interestingly, Ross and Jorgensen (1967) found that the 
hypotensive effect of verapamil in cats was totally 
accounted for by changes in the peripheral circulation, 
a principal site of action for both histamine and SRS-A. 
Drug-induced hypotension caused by the release of 
vasoactive substances from mast cells is not without 
preceden~ for Baltzby et al (1949) found that compound 
--
48/80, the "classical" agent of degranulation of mast 
cells, caused a large decrease in the blood pressure 
of dogs. Vasoactive substances released from mast cells 
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probably do not account for all of the hypotensive effect 
of verapamil as the ability of verapamil to cause the 
in vitro relaxation of smooth muscles of the vasculature 
(Rosenberger and Triggle, 1978) could also account for 
a component of the in vivo hypotensive effect of the drug. 
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CHAPTER III 
A COMPARATIVE STUDY OF THE ACTIVATION 
OF MAST CELLS BY COMPOUND 48/80 
AND VERAPAMIL 
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INTRODUCTION 
Crosslinking and Degranulation of Mast Cells; IgE 
Chapter II of this thesis examined two classes of 
drugs that caused stimulus-secretion coupling in mast 
cells. The bifunctionality of verapamil and the polymeric 
nature of compound 48/80 suggest that the drugs can act 
as crosslinking agents. This introduction briefly reviews 
the role of crosslinking and aggregation in the degranu-
lation of mast cells. 
Many of the structures involved in the degranulation 
of mast cells by antigen and IgE are understood on a 
molecular basis. For example, a specific receptor for 
IgE on rat basophilic leukemic cells has been character-
ized as a glycoprotein of molecular weight 77,000 
(Metzger, 1978). IgE binds reversibly to the receptor 
with a high affinity (Ka ~ 1010 M- 1 ) and there are ap-
proximately 106 receptors per tumor cell (Metzger et al, 
1976). 
IgE has the Y shape characteristic of immunoglobulins. 
The molecule is composed of two heavy and two light chains 
which form seven distinct globular domains. Each arm of 
the Y is composed of two such domains, (VH; VL and CHl; CL); 
the VH; VL domain contains the antigen combining site. 
The three remaining regions of the heavy chain (CH2, CH3, 
CH4) form three domains which together constitute the Fe 
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tail of the antibody; this tail contains the site which binds 
to the IgE receptor (Metzger, 1979). The primary structures 
of the E heavy chain of a human IgE-myeloma protein has been 
determined (Bennich and von Bahr-Lindstrom, 1974) as has 
the partial nucleotide sequence and the genomic location 
of the gene coding for the constant region of a mouse E 
heavy chain (Nishida et al, 1981). 
IgE binds with high affinity to its receptor in the 
absence of antigen. Such binding does not itself activate 
the mast cell nor will the binding of monomeric antigen 
to the cell-bound IgE activate the mast cell. For example, 
Siraganian et al (1975) demonstrated that bivalent antigen 
was the minimal unit required to degranulate mast cells. More-
over, Ishizaka and Ishizaka (1969) found that · crosslinking IgE 
bound to mast cells with anti-IgE antibodies caused the 
mast cell to relase histamine. Monomeric Fab' fragments 
of the anti-IgE antibodies were ineffective in degranulating 
the mast cells. Furthermore, antibodies that bound directly to 
IgE-receptors were found to trigger the release of histamine 
from mast cells (Ishizaka and Ishizaka, 1978). Monomeric 
Fab' fragments of the anti-receptor antibody were ineffec-
tive in degranulating the mast cells. This finding 
demonstrated that crosslinking of the receptors for IgE, 
regardless of IgE and antigen, was sufficient to degranu-
late the mast cell. In the same system, crosslinking of 
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the IgE receptors with antibody caused an increase in Ca++ 
permeability in the mast cells (Ishizaka et al, 1979) and 
stimulated phospholipid methylation in the mast cells 
(Ishizaka et al, 1980). Phospholipid methylation and increased 
++ permeability to Ca in the plasma membrane are early steps in 
the degranulation of mast cells caused by IgE (Hirata and 
Axelrod, 1980. Segal et al (1977) demonstrated that dimerized 
IgE, as opposed to monomeric IgE, was able to trigger the 
release of histamine from mast cells. The dimeric IgE was 
prepared by chemical crosslinking with a bifunctional re-
agent and did not require antigen for its activity. 
In summary, the evidence is overwhelming that the 
triggering of mast cells by IgE involves receptor aggrega-
tion via a crosslinking event. 
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Crosslinking and Degranulation of Mast Cells; Non-
Antibody Reagents 
A large variety of agents besides IgE are capable of 
releasing histamine from mast cells. Some of these agents 
clearly do not involve crosslinking in their mechanism. 
For example, A23187, a calcium ionophore activates mast 
cells by transporting calcium across the cell membrane 
(Cochrane and Douglas, 1974). Others, such as dextran 
with their extensive polymeric structure may trigger the 
release of histamine by the relatively non-specific aggre-
gation of cell surface receptors (Baxter and Adamik, 
1977). 
Compound 48/80 is one of a large number of poly-
cationic molecules that cause the release of histamine 
from mast cells. Among thepolycationic agents that affect 
mast cells are polylysine, protamine, somatostatin, bee 
venom mellitin, polymixin B, and bradykinin. The ana-
phylatoxins, C3a and C5a, have a large percentage of 
basic amino acids in their primary sequences (Hugli, 
1975; Fernandez and Hugli, 1976) including a carboxy-
terminal arginine that is essential for activity (Dias da 
Silva and Lepow, 1967; Cochrane and Muller-Eberhard, 
1968). 
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Sialic Acids and Neuraminidase 
Sialic acids are ubiquitous components of all 
vertebrate cell membranes (Gottschalk, 1972). The negatively 
charged sialic acids which occur as the terminal residues 
of complex heteropolysaccharides of glycoproteins are al-
most exclusively linked from carbon atom 2 of the sialic acid 
to either D-galastose (at positions 3 or 6) or to N-acetyl-D-
galactosamine (at position 3) or to other sialic acids 
(at position 8) (Tuppy and Gottschalk, 1972). In addition 
to glycoproteins, glycolipids have been found to have 
sialic acid components. For example, Hakomori and Saito 
(1969) found a glycosphingolipid on red cells that contained 
N-glycolylneuraminicacid and Kaufman et al (1968) isolated 
a similar glycosphingolipid from bird brains. On the red 
cell membrane, sialic acids account for 80% of the surface 
charge density at physiological pH as measured by micro-
electrophoresis (Herndier and Brooks, 1975). The high con-
tent of sialic acid on plasma membranes and their negative 
charge at physiological pH make sialic acids likely candidates 
for binding with the polycationic agents that cause degranu-
lation of mast cells (Baxter and Adamik, 1977). 
OH H 
N-acetylneuraminic acid 
(a sialic acid) 
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Neuraminidase is a specific enzyme which cleaves the 
terminal sialic acids off the heteropolysaccharide units 
of glycoproteins. The specificity of the enzyme is rela-
tively independent of the preceding saccharide unit but 
is sensitive to the pattern of oxygen substitution on the 
sialic acid itself (Schauer, 1973). Esterification of the 
carboxyl group of neuraminic acid blocks the action of 
neuraminidase completely (Karkas and Chargaff, 1964). This 
highly specific action of neuraminidase insures that the 
treatment of cells with the enzyme removes only sialic 
acids and does not cause non-specific damage to the cell 
membrane. 
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RESULTS 
Molecular Weight Determination of Crosslinked Verapamil 
The G-15 column was used to separate the iodinated 
crosslinked verapamil from the unreacted iodine. This 
column was previously calibrated by tritiated sugars. 
The tetrasaccharide glucose a(l + 4) glucose a(l + 3) 
glucose a(l + 4) glucose isolated from Aspergillus niger 
was obtained via a generous gift by Dr. Nordin (Tung and 
Nordin, 1970). This tetrasaccharide was reduced with 
NaBT4 (Amersham) for 16 hours at 5°C. The reaction was 
terminated by cold NaBH4 ml anti the addition of glacial 
acetic acid. Similarly 3H-glucose a(l + 4) glucitol and 
3H-glucitol were synthesized by borohydride reduction. 
The elution volumes (V) of these sugars on the G-15 
column served as molecular weight markers for the 
crosslinked verapamil. A plot of V-V0 /V0 , where v0 is 
the void volume, versus logarithm of molecular weight 
for the sugars and crosslinked verapamil is shown in 
Figure 7. 
A portion of the lyophilized 1251-crosslinked vera-
pamil was resuspended in water. Also dissolved in this 
solution were the molecular weight markers; reduced 
glutathione, vitamin . B12 , blue dextran, and bovine trypsin 
inhibitor. The mixture was separated by gel filtration 
on a Sephadex G-25 column. The 1251-crosslinked verapamil 
was monitored by gamma counting aliquots of the column 
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effluent. The column profiles of the molecular weight 
markers were determined by UV-visible spectromet!Y· A 
plot of V-Vo/Vo, were V is the elution volume and v0 is 
the void volume, versus log of the molecular weight for 
the G-25 column is given in Figure 8. 
Extrapolat"ion from Figures 7 and 8 gives a 
molecular weight of 1290 ~ 170 for crosslinked verapamil 
on the G-15 column and 1260 + 180 for the G-25 column. 
The theoretical molecular weight for a monoiodinated dimer 
with a methylene bridge is 1173. The theoretical molecular 
weights of monoiodinated monomer and monoiodinated trimer 
with two methylene bridges are 570.5 and 1514, respectively. 
A dimeric structure for iodinated cross-linked verapamil 
is proposed since only one peak was found in the 125 r-
gamma count profile and there were no significant counts 
where a trimer or a monomer would theoretically occur 
in the profile. 
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Figure 7 
Molecular weight determination of crosslinked 
verapamil gel filtration on a G-15 Sephadex column. 
The molecular weight standards were tritiated 
glucitol (182), glucose a(l+ 3) glucitol (344) 
and glucose a(l + 4) glucose a(l + 3) glucose 
a(l + 4) glucitol (668). 
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Figure 8 
Molecular weight determination of crosslinked 
verapamil: gel filtration of a G-25 Sephadex 
column. The molecular weight standards were blue 
dextran (2 x 106 ), bovine tryspin inhibitor (6518), 
vitamin B12 (1355) and reduced glutathione (307). 
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NMR Characterization of Crosslinked Verapamil 
In order to elucidate the structure of the methylene 
bridged verapamil dimer, a 500.13 MHz proton nuclear 
magnetic resonance (nmr) study was undertaken on both 
the monomer and dimer in n2o. A summary of the results 
follows. 
Figure 9 is the 500.13 MHz proton nmr spectrum for 
verapamil in n2o. The assignments of the resonances 
were obtained via homonuclear decoupling experiments. 
One interesting feature is the asymmetry of the resonances 
for the isopropyl methyl groups (o ~ 0.8, 1.2 ppm). This 
is due to the fact that, because of the sterically hindered 
nature of the isopropyl group's position in the molecule, 
rotation of the group is sever~iy hindered. Thus, the chemi-
cal shifts of the two methyl groups are affected differently 
by the ring currents of the adjacent phenyl group. 
Figure 10 shows the assigned spectrum and proposed 
structure for the methylene-bridged dimer. Most of the 
assignments were obtained using homonuclear decoupling. 
Confirmation of the existence of the bridge (o ~ 3.8 ppm) 
was obtained via a T1 experiment. Because of the immobility 
of the -CH2-bridge relative to the rapidly rotating -OCH3 
groups, the T1 of the bridge should be shorter than that 
for the -OCH3 groups was observed. The signal assigned the 
protons of the methylene bridge (o ~ 3.8 ppm) had an inte-
grated intensity of two protons per proposed dimer. 
76 
The asymmetric nature of the dimer was inferred from 
the loss of symmetry for the downf ield -CH3 groups attached 
to the isopropyl groups. If the dimer were 
symmetric, this resonance would be a clean doublet; in 
fact, it is two overlapping doublets (which appear as a 
triplet). This in conjunction with the observation of 
two N-CH3 resonances (o ~ 2.8 ppm), supports the proposed 
structure. 
The relative order of reactivity of 0-dimethoxybenzene 
to electrophilic substitution (para > ortho) and steric 
effects due to the bulky isopropyl and cyano groups (Evans, 
1981, personal communication) were also considered in deter-
mining the position of the bridGing methylene. 
In order to detect the amount of terminal aromatic 
CH20H groups within the sample, the nmr spectrum of the 
dimer was obtained in d6 -DMSO. Two resonances at o ~ 4.4 and 
4.7 ppm were found which could be assigned to such groups. 
Their total concentration in the sample is less than 10%, 
as determined by comparing their integral with that for 
both the aromatic protons and the methylene bridge. Thus, 
the predominant species has the structure shown in Figure 
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Figure 9. Proton magnetic resonance (500.13 ~JHz) spectrum and 
peak assignments of monomeric verapamil in D20. 
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Figure 11 illustrates the relative ability of compound 
48/80, crosslinked verapamil and verapamil to cause the 
release of 3H-serotonin from mast cells. Several experi-
ments were pooled and the mean concentrations of drug 
required to cause 50% of the maximum response was determined. 
The results for the release of 3H-serotonin from mast cells 
are summarized below. 
Concentration at 50% Release 
Compound 48/80 (6) 
Crosslinked verapamil (3) 
Verapamil (3) 
0.08 + 0.04 µg/ml 
6.2 + 0.2 _µg/ml 
180 + 20 µg/ml 
The effect of the treatment of mast cells with 
neuraminidase on the ability of compound 48/80, crosslinked 
verapamil and verapamil to release 3H-serotonin from mast 
cells was determined in the experiment depicted in Figure lL 
The data show that the release of 3H-serotonin from mast 
cells by compound 48/80 was inhibited by treatment of the cells 
with neuraminidase while in contrast neuraminidase treat-
ment of the cells had an insignificant effect on the re-
lease of 3H-serotonin from mast cells caused by verapamil 
and crosslinked verapamil. 
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Figure 11 
The release of 3H-serotonin from rat peritoneal cells 
challenged by compound 48/80, crosslinked verapamil 
and verapamil. The cells were isolated, loaded with 
3H-serotonin, and preincubated by the methods de-
scribed in Materials and Methods, Chapter II. Sub-
sequent experiments (Figure 16) have shown that the 
release of 3H-serotonin by crosslinked verapamil was 
as high as 95 + 5%. The challenges by compound 48/80 
(-•-•-•-•-) crosslinked verapamil (- • -• - •-) and 
verapamil (-!-4-!-!-) were for one hour at 37°C 
in MCB. The spontaneous release of 3H-serotonin (6) 
was 12%. 
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Figure 12 
Effect of neuramindase on the release of 3H-serotonin from 
rat peritoneal cells challenged with compound 48/80, 
crosslinked verapamil and verapamil. The cells were pre-
incubated withneuraminidase exactly as described in Materials 
and Methods and challenged with the various drugs for 
one hour at 37°C. The values given for release of 3H-
serotonin (cpm) were calculated by subtracting a blank 
of 1050 cpm for control cells (-•-•-•-•-) and 1350 cpm 
for cells pretreated withneuraminidase (----0----0----0----). 
The molar concentrations of the drugs were calculated assuming 
that crosslinked verapamil is a dimer and compound 
48/80 has a molecular weight of 800 as determined 
by Morrison et al (1974). The curves at the left are 
compound 48/80, the curves in the middle are crosslinked 
verapamil and the curves on the right are verapamil. 
The estimated error on the cpm of the released 3H-
serotonin was 5%. 
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Table III shows the results of two experiments examining 
the role of crosslinking of antigen in the release of 
3H-serotonin from mast cells by the IgE-14-205 protein. 
The crosslinking of ovalbumin by Woodward's reagents K 
and the relatively complex protocol of this experiment 
are described in detail in the Materials and Methods 
section. The addition of only crosslinked ovalbumin or 
only ovalbumin to the mast cells did not cause a significant 
release of SH-serotonin (not shown). The results of 
Table III are seen to indicate that crosslinked ovalbumin 
cause a greater release of 3H-serotonin from IgE-treated 
mast cells than monomeric ovalbumin. 
Figure lSrepresents dose-response curves for the 
release of SH-serotonin from mast cells challenged with 
compounf 48/80 at various concentrations of extracellular 
calcium. The results show that increases in the concen-
tration of extracellular calcium causes a decrease in the 
ability of compound 48/80 to induce the release of 3H-
serotonin from mast cells. This result agrees qualita-
tively with the preliminary finding of Kagayama and Douglas 
(1974), that 110 mM Cac1 2 in the extracellular abolished the 
degranulation of mast cells caused by compound 48/80. 
Figure 14 shows the effect of extracellular calcium 
concentration on the release of 3H-serotonin from mast 
cells challenged with verapamil. The release of 3H-serotonin 
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at the submaximal dose of verapamil (179 µg/ml) was rela-
tively uneffected by the concentration of extracellular 
calcium. 
Figure 15 shows the effect of the concentration of 
LaC1 3 on the uptake of 
45
ca into P815 mastocytoma cells. 
At concentrations of LaC1 3 greater than approximately lmM, 
the La+++ caused a dose-dependent increase in the uptake 
of 45ca into the mastocytoma cells. 
Figures 16 and 17 illustrate timed experiments 
examining the kinetics of the release of 3H-serotonin 
from rat mast cells by compound 48/80, crosslinked 
verapamil and verapamil. Figure 16 shows that relatively 
high concentrations of verapamil and crosslinked verapamil 
cause the release of 3H-serotonin from mast cells. This 
experiment illustrates that a component of the release 
of 3H-serotonin by verapamil and crosslinked verapamil 
is fast (< 5 minutes). Similarly, the data of Figure 17 
show that relatively low concentrations of these drugs 
could cause this same fast component (< 5 minutes) of 
release of 3H-serotonin from the mast cells. 
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Table III Release and Retention of 3H-Serotonin in Mast 
Chapter I II 
Cells Preincubated in IgE 14-205 Protein Then 
Challenged by Crosslinked Ovalbumin or Ovalbumin 
[IgE] [Ovalbumin] % Release % Retention 
0.50 µM 18.0 µM x 80 20 
0.50 µM 18.0 µM 45 55 
0.50 µM 0 100 
0.14 µM 6.0 µM x 22 78 
0.14 µM 6.0 µM 19 81 
0.14 µM 0 103 
0.14 µM 2.0 µM x 46 54 
0.14 µM 2.0 µM 28 72 
0.14 µM 2 98 
0.27 µM 5.8 µM x 59 41 
0.27 µM 5.8 µM 36 64 
0.27 µM 9 91 
1.08 µM 20.7-µM x 46 54 
1.08 µM 20.7 µM 48 52 
1.08 µM 9 91 
0.27 µM 12.4 µM x 46 54 
0.27 µM 12.4 µM 0 101 
0.27 µM 0 115 
X refers to crosslinked ovalbumin 
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Figure 13 
Effect of calcium concentration on 3H-serotonin 
release from rat peritoneal cells challenged by 
compound 48/80. The rat peritoneal cells were 
isolated in regular MCB which contains no calcium. 
The cells were preincubated in various concentra-
tions of CaC1 2 for 15 minutes at 37°C. The cells 
were then challenged by compound 48/80 for one 
hour at 37°C. The (-0-0-0-0-) curve represents 
cells preincubated in HCB containing no calcium. The 
(-•-•-•-•-) curves represent cells preincubated 
++ in 2 mM Ca (upper) and 6 mM calcium (lower). 
The estimated error was 5%. 
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Figure 14 
Effect of calcium concentration on 3H-serotonin 
release from rat peritoneal cells challenged 
with verapamil. The rat peritoneal cells were 
isolated in regular MCB which contains no calcium. 
The cells were then preincubated in various con-
centrations of CaC1 2 for 10 minutes at 37°C. The 
cells were then challenged for one hour at 37°C 
wtih 510 µg/ml of verapamil (-•-•-•-) and 179 µg/ml 
of verapamil (-'-A-i-!-). The estimated error 
was 5%. 
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Figure 15 
The effect of lanthanum concentration on calcium 
uptake in P815 mastocytoma cells. The P815 cells 
were aliquoted into MCB containing 2 mM ca++ and 
45
ca at a specific activity of 0.58 µmole/10 6 cpm. 
After a short preincubation the P815 cells (1.3 x 
6 10 cells per 1 ml sample) were exposed to various 
concentrations of LaC1 3 for 20 minutes at 37oc. 
The cells were then worked up on glass filters as 
described in Materials and Methods. The error 
in this experiment was large and was estimated 
from the standard deviation of the values for the 
blanks to be + 3 nmoles Ca/106 cells. 
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Figure 16 
Rate of release of 3H-serotonin from rat peritoneal 
cells challenged with high concentrations of 
verapamil and crosslinked verapamil. The cells 
were preincubated and challenged by the usual 
methods except that aliquots were sampled at 
various time intervals from large volumes (10 ml). 
Scintillation counting of the supernatants of the 
aliquots determined the release of 3H-serotonin. 
The blank at 0 minutes was 4% of the total 3H-
serotonin release and at 91 minutes was 7% of 
the total 3H-serotonin release. The concentration 
of verapamil was 880 µg/ml (-•-•-•-•-) and cross-
linked verapamil 40 µg/ml (---0---0---). 
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Figure 17 
Rate of release of 3H-serotonin from rat peritoneal 
cells challenged with crosslinked verapamil, vera-
pamil, and compound 48/80. The cells were prein-
cubated and challenged by the usual methods except 
that aliquots were sampled at various time intervals 
from large volumes (6 ml) of rat peritoneal cells in MCB. 
Scintillation counting of the supernatants of the 
aliquots determined the release of 3H-serotonin 
from the cells. The various drug concentrations 
were: 
compound 48/80 0.16 µg/ml 
-·-·-·-
verapamil 330 µg/ml 
-·-·-·-cross linked verapamil 5 µg/ml -!:::.-!:::.-!:::.-
blank -0-0-0-
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DISCUSSION 
Crosslinking and aggregation of IgE-receptors on the 
mast cell surface has been proposed as an obligatory 
event in the degranulation of mast cells (Metzger, 1979). 
A mechanism of action of verapamil and crosslinked vera-
pamil might feature the drugs crosslinking cell surface 
structures in a manner analogous to the activation of mast 
cells by crosslinking IgE-receptors (Hirata and Axelrod, 
1980) system. In fact, a chemically crosslinked deriva-
tive of verapamil was 30 times more potent by weight at 
causing the release of 3H-serotonin from rat mast cells 
relative to monomeric verapamil (Figure 11). 
We attempted to further examine the role of cross-
linking and aggregation of cell surface structures by 
comparing the relative ability of chemically crosslinked 
ovalbumin versus monomeric ovalbumin to cause degranulation 
of mast cells in the presence of an IgE hybridoma protein 
that specifically binds to ovalbumin. The data of 
Table 1 show that ovalbumin crosslinked with Woodward's 
reagent K caused a greater release of 3H-serotonin from 
rat mast cells preincubated in the IgE-14-205 protein 
than monomeric ovalbumin. This result does seem to agree 
with the general findings of Siraganian et al (1975) and 
others that chemically crosslinked antigen causes a 
greater IgE-mediated release of histamines than monomeric 
antigen. 
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Moreover,verapamil has a crude symmetry around the 
tertiary amino group making it a possible candidate for 
a bifunctional agent capable of crosslinking. The increased 
ability of crosslinked verapamil to cause the release 
of 3H-serotonin from mast cells may be due to the avail-
ability of more methoxyphenyl rings for binding to cellu-
lar target structures. 
The increased binding of a crosslinked molecule, 
relative to its monomeric counterpart, to another struc-
ture may be analogous to the so-called thermodynamic 
"chelate effect" for metal ions (Cotton and Wilkinson, 
1972). The chelate effect refers to the enhanced stability 
of a metal complex system containing ring-forming ligands 
as compared to a system with similar monomeric ligands. 
The entropy for the formation of such chelates is 
significantly more favorable than that for the formation 
of an analogous complex from a metal ion and several 
ligands. In forming the chelate, the translational 
entropy of only one molecule is lost; in forming the 
multiliganded complex, the translational entropy of sev-
eral molecules must be sacrificed. 
Besides simple thermodynamic considerations, the in-
creased ability of crosslinked verapamil to cause release of 
3H-serotonin from mast cells relative to verapamil may be 
due to steric considerations in the crosslinking potential 
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of the drugs. For example, crosslinked verapamil may be 
able to span and consequently link sites that cannot be 
linked by monomeric verapamil. 
IgE binds to a specific glycoprotein on the mast cell 
surface (Metzger, 1979). Moreover, there is some circumstantial 
evidence that verapamil and D-600 can also bind to pro-
teins. For example, Kaumann and Uchitel (1976) found 
significant differences in the (+) and (-) isomers of 
verapamil in their ability to inhibit potassium-induced 
contractures in frog skeletal muscle fibers. Furthermore, 
the (+) and (-) isomers of verapamil were shown to have 
different abilities to cause the decoupling of excitation 
from contraction in canine heart (Kaumann and Serur, 
1975). The stereoselective pharmacology of (~)-verapamil 
suggests that the drug is binding to stereoselective sites 
on proteins. 
Discussion of Neuraminidase 3esults 
Experiments were designed t~ determine if verapamil 
interacts with the cell surface to cause degranulation 
of mast cells in a manner analogous to the binding of IgE 
to its receptor or if verapamil triggers degranulation by 
some intracellular mechanism of action. 
Rat peritoneal cells were treated with 
neuraminidase, an enzyme that specifically removes sialic 
acids from cell surface molecules, and then challenged 
with verapamil, crosslinked verapamil, and compound 48/80 
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(Figure 12). Pretreatment of the cells with neuraminidase 
abolished the ability of compound 48/80 to cause release 
of 3H-serotonin from mast cells (Figure 12). Similarly, 
Baxter and Adamik (1977) had found that pretreatment 
with neuraminidase causes a significant decrease in the 
release of histamine from mast cells exposed to compound 
48/80, protamine and polylysine. They also found that 
the neuraminidase pretreatment did not affect the ability 
of antigen to evoke IgE-mediated release of histamine 
from mast cells. Figure 12 shows that pretreatment of the 
cells with neuraminidase did not significantly affect 
the ability of verapamil or crosslinked verapamil to cause 
release of 3H-serotonin from rat peritoneal cells. 
These results indicate that the exact sites of action 
of compound 48/80 and verapamil are different. Compound 
48/80 causes degranulation of mast cells by binding to the 
sialic acids of cell surface molecules that are sensi-
tive to hydrolysis by neuraminidase. In contrast, vera-
pamil almost certainly does not require these neuraminidase-
sensi ti ve sialic acids to cause the release of 3H-serotonin 
from mast cells. Conceivably, the verapamil and compound 
48/80 could even by interacting with the same molecule. 
As a hypothetical example, the verapamil interacts with the 
protein portion of a glycoprotein and compound 48/80 binds 
to the saccharide groups of this same glycoprotein but 
there is not direct evidence for this hypothesis. 
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A simple way to explain why verapamil and crosslinked 
verapamil are not inhibited in their ability to cause 
the release of 3H-serotonin from mast cells when the 
cells were pretreated with neuraminidase is to propose 
that these drugs act inside the cell to trigger the re-
lease of 3H-serotonin. Other studies have inferred that 
verapamil not only blocks the so-called "slow channels" 
for Ca++ in the plasma membrane (Fleckenstein, 1977) 
but causes other effects by acting within the cell. For 
example, Church and Zsoter (1980) found verapamil in-
hibited the contraction of rabbit mesenteric vein caused 
by high concentrations of extracellular potassium. The 
drug did not alter the lanthanum-resistant uptake* of 45ca 
by the vein during the verapamil-induced relaxation, im-
plying that the effect was not due to the drug acting as 
a specific antagonist of the calcium channels of the plasma 
membrane but had an intracellular mechanism of action. 
Moreover, verapamil has been shown to inhibit the nore-
pinephrine-induced development of tension in the isolated rat 
atrium (Church and Zsoter, 1980). Norepinephrine caused a 
*The 'l~nthanum-method" supposedly allows the direct measure-
ment of 45ca influx by cell and tissues without interference 
due to binding of the 45ca to the cell surface and efflux of 
the label from the tissue (Van Breeman et al, 1973). However 
have found that La3+, itself, causes a dose-dependent uptake 
of 45ca into P815 mastocytoma cells (Figure 15) and similarly, 
Foreman and Mongar (1972) found that high concentrations of 
La3+ caused mast cells to release histamine, a ~rocess that 
can be caused by an influx of extracellular ca+ (Hirata and 
Axelrod, 1980). 
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rapid increase in tension that could be inhibited by verapamil. 
Church and Zsoter (1980) proposed that verapamil had an 
intracellular mechanism of action, supposedly by inter-
fering with the distribution of calcium in the intracellu-
lar pools. However, this is not conclusive evidence since 
verapamil could act at the cell surface and exert its 
effect on the norepinephrine-induced tension via a mechanism 
involving a secondary messenger. 
Similarly, we have shown that verapamil can cause the 
release of 3H-serotonin from mast cells in the absence 
of extracellular calcium; moreover the release was rela-
tively insensitive to the concentration of extracellular 
calcium (Figure 13). These results are in contrast to 
those for the release of biogenic amines from mast cells 
challenged with compound 48/80; in this case release was 
significantly inhibited by the addition of extracellular 
calcium (Figure 14). These experiments suggest that the 
release of 3H-serotonin from mast cells caused by vera-
pamil is not due to an influx of extracellular calcium 
analogous to the mechanism of degranulation of mast cells 
by IgE-aatigen complexes (Hirata and Axelrod, 1980). 
Discussion of Possible Mechanisms 
Verapamil causes a wide variety of effects on 
mammalian myocardium, some of which cannot be explained 
by blockage of the so-called "slow calcium channels" 
(Bayer et al, 1975). For example, Bayer et al (1975) 
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found that the (~)-isomers of verapamil and D-600 have a 
quite specific inhibitory effect on the fast Na+ inward 
current in feline myocardium. The (+)-isomers also in-
creased the threshold intensity of electrical stimuli 
needed to elicit conducted action potentials in the 
myocardium. Bayer et al (1975) also found that the (-)-
isomers of verapamil and D-600 were more potent than the 
(+)-isomers in blocking the so-called specific calcium 
channels in the myocardium. This local anesthetic effect 
of verapamil and D-600 has also been shown in frog nerves 
where the drugs are l.6X times more active than procaine 
in blocking action potentials (Singh and Williams, 1972). 
A mechanism of action similar to the cationic 
anaesthetic effect of verapamil could provide a molecular 
rationale for the ability of verapamil to release 3H-
serotonin from mast cells. Seeman (1972) and Kwant and 
Seeman (1969) have shown that local anaesthetics such 
as phenothiazines displace membrane calcium from erthyro-
cyte ghosts and Sheetz and Singer (1974) suggested that 
cationic anaesthetics bind to the cytoplasmic side of 
the membrane bilayer which is relatively rich in the nega-
tively charged phospholipids such as phosphatidylserine 
(Bretcher, 1972). The cationic drugs supposedly expand 
the cytoplasmic side of the bilayer and induce cup forma-
tions in erythrocytes. Furthermore, Frazier et al (1970) 
showed with microinjection techniques that the anaesthetic 
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action of several tertiary amine local anaesthetics was 
more effective on the cytoplasmic side of the nerve mem-
brane. In accord with the above observations, verapamil 
may displace membrane-bound calcium from the cytoplasmic 
side of the plasma membrane and thereby trigger the 
release of granule-stored amines from mast cells. 
Unfortunately, the mechanism of action of cationic 
anaesthetics have not been resolved, but the anaesthetics 
do cause a variety of effects that could conceivably 
increase the cytosolic [Ca++] enough to activate mast 
cells. For example, positively charged anaesthetics 
displace loosely adsorbed Ca++ from reticulum membranes 
++ (Thorpe and Seeman, 1971) and reduce the entry of Ca 
across mitochrondrial membranes (Tjioe et al, 1971). 
Furthermore, there is experimental evidence that high 
concentrations of verapamil affect the translocation 
of calcium across in vitro preparations of subcellular 
membrane fractions. For example, high concentrations of 
verapamil have been shown to inhibit calcium uptake by 
membrane and endoplasmic reticulum fractions from 
rabbit aorta (Thorens and Haeusler, : 1979). Moreover, 
Crankshaw et al (1977) found that D-600 (520 µg/ml) and 
++ 
verapamil (490 µg/ml) significantly reduced Ca accumu-
lations in subcellular fractions of the plasma membrane, 
endoplasmic reticulum, and the mitochrondrial membrane of 
rat myometrium. Lastly, Balzer (1972) found a similar 
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effect for verapamil in an in vitro membrane fraction 
of the sarcoplasmic reticulum of skeletal muscle. Perhaps, 
verapamil causes an increase in the concentration of 
cytosolic Ca++ by inhibiting the calcium-ATPase pumps of 
membranes defining the cytosolic pool. This event may 
trigger the release of histamine by mast cells challenged 
by verapamil. An unanswered question is whether the in 
vitro inhibition of calcium-ATPase pumps by verapamil 
in subcellular membrane fractions is relevant to the intact 
mast cell. 
Verapamil could possibly interact with the ubiquitous 
++ intracellular Ca -receptor, calmodulin, and cause the 
degranulation of mast cells. Calmodulin has been implicated 
in a wide variety of calcium-dependent effects such as 
activation of a phosphodiesterase (Cheung, 1970) an adenyl 
cyclase (Bronstron et al, 1975) a phospholipase A2 in 
platelets (Wong and Cheung, 1979) and ATPase-dependent 
calcium pumps of erythrocyte membranes (Levine and Weiss, 
1980). Some or all of these effects could be postulated 
to affect degranulation of mast cells depending on 
whether verapamil potentiates or counteracts the action 
of calmodulin. However, such speculation is pointless 
until the existence of sufficient calmodulin has been 
demonstrated in the mast cell. 
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Kinetics of the Release of SH-Serotonin from Mast Cells 
The kinetics of the release of SH-serotonin by 
verapamil and crosslinked verapamil show interesting 
features (Figures 16 and 17). At concentrations of 
verapamil and crosslinked verapamil that do not cause 
maximal release of SH-serotonin, the pattern of release 
appears to be biphasic. For release of SH-serotonin 
caused by verapamil or crosslinked verapamil, there 
appears to be a fast release (< 5 minutes) followed by 
a lag time then a slower release (Figure 17). A possible 
explanation of this biphasic kinetics is that the drugs 
first cause a release of SH-serotonin by interacting 
with the cell surface, in a manner analogous to compound 
48/80, then penetrate the membrane and interact with 
intracellular targets to bring about the slow release. 
In accord with this possibility, the crosslinked verapamil 
showed a larger release of SH-serotonin in the·fast phase 
then did monomeric verapamil; nevertheless crosslinked 
verapamil showed a lower overall release of SH-serotonin 
from the mast cells. This increased ability of cross-
linked verapamil to cause the fast release of SH-serotonin 
from mast cells could be due to its ability to aggregate 
cell surface molecules as a crosslinking agent in a manner 
analogous to the polymeric compound 48/80. In contrast, 
monomeric verapamil could be more effective in the slow 
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phase of release of 3H-serotonin simply because higher 
concentrations of the drug are penetrating the membrane 
and interacting with intracellular targets. 
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CHAPTER IV 
A STUDY OF CONTRACTURE OF SKELETAL 
MUSCLE CAUSED BY COMPOUND 48/80 
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INTRODUCTION 
Muscle Contracture As A Model for Excitation-Contraction 
Coupling 
A muscle contracture has been defined as a decrease 
in the length of a muscle or an increase in muscle ten-
sion produced without muscle action potential (Gasser, 
1930). In contrast, muscle twitches require 
a muscle action potential and are designated as contrac-
tions. 
A difficulty in studying excitation-contraction 
coupling in skeletal muscle is separating the complex 
ionic events involved in the generation of the action po-
tential from possible ionic or biochemical events associated 
with the actual coupling of the action potential 
with the release of calcium from the sarcoplasmic 
reticulum. Muscle contractures, because they do not depend 
on muscle action potentials, offer a simpler system for 
study. However, use of muscle contractures as a basis for 
inferences on excitation-contraction coupling should 
involve great caution because of the possible non-physio-
logical nature of the experiment. However, in the past 
contracture systems have provided useful models for ex-
citation-contraction coupling. For example, there is the 
so-called potassium contracture which features the de-
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polarization of the muscle membrane by replacement of 
Na+ by K+ in the extracellular medium. Frank (1964) 
demonstrated that the removal of extracellular caicium 
abolishes the potassium contracture but does not affect 
the depolarization of the muscle membrane. This result 
suggested that the extracellular calcium pool was the 
source of "trigger-Ca++" in the potassium-contracture. 
A more thorough analysis of the kinetics of the removal 
of calcium in potassium-contracture suggests that the 
rate of exchange of "trigger-Ca++" was intermediate be-
tween the rate of exchange of extracellular calcium, 
which was rapid, and the rate of exchange of intracellular 
calcium of the sarcoplasmic reticulum, which was shown to 
be slow (Frank, 1979). Similarly, muscle contractions can be 
abolished in buffer without calcium, but only after Ca++ has 
been removed for approximately ten minutes. This is much 
longer than the few seconds required for Ca++ to diffuse out of 
the t-tubular system and shorter than the estimated four 
hours required to significantly deplete the pool of calcium 
in the sarcoplasmic reticulum (Frank, 1979). The 
parallel finding for the potassium-contracture of skeletal 
muscle and the contractions of skeletal muscle caused 
by an action potential seem to imply that the source of 
"trigger-Ca++" is the same for both systems and is likely 
to be membrane-bound calcium. 
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Caffeine causes a contracture in skeletal muscle at 
concentrations greater than 3.0 mM (Axelsson and The.sloff, 
1958). This contracture does not require extracel~ular 
calcium and does not cause depolarization of the sarcolemma. 
Caffeine is believed to act directly on the sarcoplasmic 
reticulum and to cause calcium release from that organelle 
(Ebashi, 1976). The molecular mechanism of this release 
is not known. This contracture system has limited utility 
for understanding EC coupling between the t-tubules and 
the sarcoplasmic reticulum but may be of use in under~ 
standing the function of the sarcoplasmic reticulum 
(Hasselbach, 1980). 
This study involves the development of an experimental 
model of excitation-contraction coupling. We have found 
that compound 48/80, a promoter of stimulus-secretion 
coupling in mast cells causes a contracture in muscle. 
The possibility of a mechanistic link between stimulus-
secretion coupling in mast cells and excitation-contraction 
coupling in skeletal muscle was investigated using the 
compound 48/80 to induce muscle contracture. 
115 
Protein Turnover in Muscle 
Continuous protein turnover is a feature of muscle 
and many other tissues and cells (Goldberg and St. John, 
1977). Protein degradation. as well as protein synthesis 
is precisely regulated in the normal cell. Protein 
breakdown may function to remove abnormal proteins, to 
degrade enzymes or structures not needed in the immediate 
function of the cell, and to provide amino acids for 
other tissues under nutritional stress. The rates of 
protein synthesis and degradation in tissues can be 
changed by extracellular signals such as hormones and 
by the activity of the tissue. Protein turnover ultimately 
can determine the growth, stability or atrophy of tissue. 
There is evidence that protein turnover in normal 
and pathological muscles is sensitive to the distribu-
tion of calcium in the intracellular pools. Kameyama 
and Etlinger (1979) had found that protein turnover in 
rat soleus muscles could be affected by treatment of the 
muscles with the Ca-ionophore, A23187. Pennington (1978) 
proposed that muscular dystrophy, a disease characterized 
by abnormalities in protein turnover, might also exhibit 
abnormalities in cellular calcium metabolism. 
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Chapter II of this thesis presents evidence that, 
in mast cells, compound 48/80 can mobilize intracellular 
stores of calcium leading to degranulation of the cell. 
In the normal excitation-contraction cycle of skeletal 
muscle the muscle action potential triggers a series 
of events which lead to the mobilization of calcium 
from the intracellular organelle, the sarcoplasmic reticulum 
(Hasselbach, 1980). Since compound 48/80 causes a con-
tracture in frog skeletal muscle, we were interested in 
a possible relation between protein turnover and the 
mobilization of intracellular calcium in frog skeletal 
muscle challenged with compound 48/80. 
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MATERIALS AND METHODS 
Isolation of Frog Skeletal Muscles 
The muscles were isolated from frogs of the genus 
Rana pipiens (Carolina Biological). The frogs were ·double 
pithed and pinned down. The skin was cut away from the 
leg and the exposed muscles were kept wet by oxygenated 
frog Ringer's solution. All muscles were removed by a 
technique such that the tendons of origin and insertion 
could be easily cut with no damage to the muscle membrane. 
Fine pointed forceps and corneal scissors proved indis-
pensible to this task. The muscles removed, with the 
ranges in masses, were: the sartorius (80-400 mg), 
semitendinosus (70-300 mg), semimenbranosus (280-1200 mg), 
gracilis major (240-950 mg), gastrocnemius (420-1940 mg), 
and a tightly bound complex of the peronius, tibialis 
articus and tibialis posticus (220-800 mg). This "shin 
muscle" complex was not separated for fear of damaging 
the muscle membrane. When more than one frog was used 
in an experiment care was taken to match their sizes. 
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Denervation of the Sartorius Muscle 
Intact frogs were set in 10% ethanol until they 
ceased to show any movement reflexes. A small (~ 2 cm) 
incision was made over the sartorius muscle. The other 
leg was left intact to later serve as a control. With 
fine point forceps and corneal scissors the sartorius 
muscle was separated from the gracilis major muscle to 
expose the sartorius nerve. Care was taken to avoid 
damaging the muscles. The nerve was cut causing a con-
traction/twitch of the sartorius. The skin was closed 
with wound clips and after a week the sartorius muscles 
were isolated and submitted to pharmacological challenge. 
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Treatment of Frog Muscles with Neuraminidase 
Frog skeletal muscles were treated with neuraminidase 
derived from Vibrio cholerae (Calbiochem-Behring) .. 
Typical experiments exposed the muscle to 0.25 units/ml 
in 0.7 ml of PAB for 75-90 minutes at 25°c. The muscles 
were then transferred to another PAB aliquot and subjected 
to the various pharmacological challenges. One unit of 
neuraminidase activity is defined as the amount of enzyme 
that will release 1 µmole of N-acetylneuraminic acid from 
human acid a 1-glycoprotein per minute at 37°C in 0.05 M 
sodium acetate buffer, pH 5.5 containing 5 mM calcium 
chloride. 
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Measurement of the Efflux of 86Rb+ from Frog Mu~~le 
MuseJ.cs were preincubated in 10 µCi/ml of 86RbCl in 
PAB at 25°C for 1.5 hours. The excess 86Rb+ was ~ashed 
from the muscles by dipping them in a large volume of 
PAB then incubating the muscles in a 5 ml volume of 
the buffer. Thewashwas then repeated. The rationale 
for this procedure was to remove loosely associated 
86Rb+ from the muscle. After this preparation, the 
muscles were put into plastic tubes containing PAB 
and challenged with the various pharmacological agents. 
Aliquots of the extramuscular buff er were sampled and 
analyzed by the standard methods of scintillation 
counting. 
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Protein Degradation Measurements 
All experiments involving protein degradation ~ere 
performed in protein anabolism buffer (PAB). PAB is a 
balanced buffer specifically designed to maintain protein 
synthesis. The amphibium PAB was modified from the basic 
frog Ringer buffer with adaptation from a mammalian muscle 
system (Kameyama and Etlinger, 1979). PAB consisted of 116 mM 
NaCl, 2.5 mM KCl, 2 mM MgC1 2 , 10 mM Tris(hydroxymethyl)amino-
methane, 10 mM glucose, 1.8 mM CaCl2, 1.0 mM isoleucine, 
1.0 mM leucine, 1.0 mM valine and 10 units/£ insulin. The 
PAB was titrated to pH 7.4 with concentrated hydrochloric 
acid. 
The isolated frog muscle was incubated in PAB at 
25°c. After a specific drug challenge the muscle was 
placed in PAB containing 10% trichloroacetic acid (TCA). 
The original PAB was also made 10% in TCA. The TCA 
served three purposes: to precipitate any exogenous 
protein released by the muscle; to precipitate the drug 
48/80 to prevent interference with the subsequent 
tyrosine assay and to precipitate the protein of the 
intact muscle so that the muscle could easily be broken 
up to release internal pools of tyrosine. The muscles 
were generally left overnight at 5°C before being broken 
up by manual manipulation with a glass stirring rod. 
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Each muscle of a given experiment was manipulated for 
approximately the same time. The precipitated muscle 
debris was pelleted by centrifugation and the supernatant 
was analyzed. It was found that the muscles could be 
broken up very easily by the addition of an aliquot of 
saturated sodium carbonate solution to the TCA precipi-
tated muscle. This approach was tried in several experi-
ments and was believed not to the assay. 
The supernatant of the original reaction volume 
(containing released tyrosine) and the supernatant of 
the precipitated muscle (internal tyrosine pool) were 
analyzed by the spectrofluorimetric method of Waalkes 
and Udenfriend (1957). The assay consisted of deriva-
tizing tyrosine with l-nitroso-2-napthol and analyzing 
the extracted product spectrofluorimetrically (activa-
tion 460 mµ; measurement 570 mµ). The instrument 
used was a Perkin-Elmer MPF-4 fluorescence spectrometer. 
kindly loaned by Dr. M. A. Raftery. In most experiments 
the total protein degradation was cited as the sum of 
the released tyrosine and the internal tyrosine pool. 
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Origin and Maintenance of L8 Myoblast Cell Line 
The L8 cell line was a gift of Dr. H. Blau of Stanford 
University (Blau and Epstein, 1979). The line was or-
ginally derived from newborn rat skeletal (thigh) muscles 
(Yaffe, 1968). These cells retain the ability to fuse to 
form multi-nuclear syncytia (myotubules). Upon formation 
of the myotubules the L8 cells cease division and DNA 
synthesis and synthesize a number of proteins of 
myotubules including myosin and the muscle isozymes of 
creatine kinase. 
The L8 myoblasts were grown at 37°C in 5% co2 /100% H20 
in Waymouths media supplemented with 10% fetal calf serum. The 
~reconf inement monolayers were passed by first washing the 
cells with Ca and Mg - free Dulbecco's phosphate buffered 
saline and then digesting the monolayer for three minutes 
at 37oc with 0.125% trypsin. 
1:10 to 1:20. 
The cells were split 
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Protein Degradation in L8 Cells 
The cells were grown from low density to approxi-
mately 5 x 105 cells per plate. The growth medium was 
washed off the monolayer with several rinses of PBS. 
1.5 µ£ of PAB, adjusted with NaCl for mammalian cells, 
was added to the plates. The cells were challenged 
with 48/80 for one hour. After this treatment 0.25 ml 
of 30% TCA was added to 1 ml of the supernatant to pre-
cipitate protein and drug. One ml of 30% TCA was then 
added to the remaining 0.5 ml of PAB. The monolayer 
of precipitated cells was mechanically detached from 
the tissue culture plate by a rubber policeman. Both 
aliquots were centrifuged to remove the TCA precipitate 
and the supernatant analyzed for tyrosine. The total 
of the two aliquots represented the total free tyrosine 
in the L8 cells. Differences in free tyrosine levels 
indicated protein degradation by the assumptions of 
Kameyama and Etlinger (1979). 
45 Measurement of Ca Uptake 
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In a typical muscle calcium exchange experiment, muscles 
were exposed to 45cacl2 in the presence of 25°c PAB. The 
45
ca was 1 µCi/ml in a 2 ml volume. The specific activity 
of the 45ca was 5 x 104 cpm/µmole Ca at a concentration of 
1.8 mM CaC1 2 . After the designated time period for the 
challenge the muscles are serially washed in 5 ml PAB. 
After four washes (~ 15, 15, 30, 30 minutes) the external 
45
ca counts have stabilized at a level of~ 0. 4% of the 
original specific acitivity. Because the wash counts 
had stabilized at such a low value, it was assumed that 
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all "loosely" bound surface Ca had been removed from 
the muscle. The muscles were then digested in 3 N nitric 
acid on a steam bath for two hours. Muscle debris, if any 
was present after the digestion, was centrifuged and an 
aliquot of the supernatant was taken. The aliquots were 
neutralized with an aqueous sodium hydroxide 
solution. The 45ca was then counted on a Beckman scintil-
lation counter. 
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Assay of Protein Synthesis in Frog Skeletal Muscle 
The muscles were preincubated in oxygenated protein 
anabolism buffer (PAB) at 2s0 c for 20 minutes. The PAB 
had been made 0.6 µCi/ml with 14C-tyrosine (Amersham) 
and 0.5 mM with cold tyrosine. The muscle was challenged 
in this medium for ~ 1 hour in presence of a drug or in 
the absence of drug as a control. Then the muscle was 
treated with 30% trichloroacetic acid (TCA) at 
s0 c for at least 12 hrs. The muscle-TCA tube was spun 
at 2,000g for 10 minutes. The supernatant was collected 
and extracted three times with diethyl ether to remove 
the TCA which can interfere with the scintillation 
counting. An aliquot was counted to determine the amount 
of 14c-tyrosine present. Another aliquot was taken to 
determine the amount of tyrosine present in the cyto-
plasmic pools. The tyrosine was measured by the Waalkes 
and Udenfriend (1957) method described elsewhere in this 
study. The TCA precipitate (the bulk of the muscle) was 
washed then solubilized in 6N NaOH for several hours in 
a steambath. An aliquot of this mixture was neutralized 
and counted. This count represented the amount of 14c-
tyrosine incorporated into the muscle protein. Total 
tyrosine incorporation was determined by dividing the 
specific activity of the cytoplasmic pool of tyrosine by 
the total 14c-tyrosine incorporated into the muscle protein. 
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Protein synthesis was expressed as pmoles tyrosine incor-
porated in 1 mg of muscle per hr. 
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RESULTS 
General 
Isolated frog muscles undergo a readily observable 
contracture when exposed to the drugs; compound 48/80 
and verapamil. Typical concentrations that would cause 
a readily observable contracture in the muscle were: 
500 µg/ml-2 mg/ml for compound 48/80 and 1.3 mg/ml of 
verapamil. The contractures were characterized by a 
significant change of length in the muscle (~ 40% for 
the sartorius) and the development of rigor or loss 
of plasticity. The general description of the contracture 
caused by compound 48/80 was very similar to the caffeine-
induced contracture/rigor described by Schwartz et al 
(1978). 
The contractures were often scored on a relative 
basis. A slight change in the morphology of a muscle 
relative to a untreated control muscle was given a value 
of one plus (+). A large or maximum contracture was 
given a value of four pluses (++++). If no difference 
was observed between the untreated control muscle and 
the treated muscle, the treated muscle was scored as 
"no contracture". The scoring system though semi-
quantitative, is reproducible. For example, no contrac-
tures were ever observed on the muscles exhaustively 
pretreated with neuraminidase. Control muscles for 
the neuraminidase experiment treated with compound 48/80 
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(between 1 mg/ml and 2 mg/ml) always elicited a strong con-
tracture response. 
Our focus was on the ionic events associated with 
contracture and with protein turnover during the contrac-
ture. The experiments were usually designed to get the 
maximum contracture response such that differences in 
ionic flux or protein turnover between treated muscles 
and control muscles would be significant for a small 
number of samples. 
Muscle contracture caused by compound 48/80 was tested 
for its dependence on a nerve-muscle interaction De-
nervated frogsartorii in which the nerve had been allowed 
to atrophy were observed to undergo the same contracture 
in the presence of compound 48/80 as a sartorius muscle 
not surgically altered. The denervatedsartorii showed 
the same characteristic compound 48/80-dependent increase 
in 45ca-uptake (2-3 fold) relative to control as the non-
surgically altered sartorius muscle. 
A preliminary experiment indicated that treatment of 
the sartorius muscle with EDTA (2 mM for 20 minutes) could 
diminish, but did not abolish, the contracture caused by 
48/80. Frog skeletal muscles bathed in PAB with no Ca++ and 
challenged with compound 48/80 showed no observable difference 
in contracture or rate of protein degradation relative to 
muscles incubated in the normal 1.8 mM Ca++ PAB. 
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Neuraminidase and Skeletal Muscle 
Neuraminidase treatment of frog skeletal muscles pre-
vented the observable contracture caused by compound 
48/80. Similarly, the release of 3H-serotonin from 
mast cells was inhibited by pretreatment of the cells 
with neuraminidase (see Chapter III, Figure 12). 
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Efflux of 86Rb+ From Skeletal Muscle 
The results of Figures 18 and 19 show the effects 
of verapamil and compound 48/80 on the efflux of 86Rb+ 
from frog skeletal muscles. 
Figure 18 illustrates the dose-dependent increase in 
86 + the initial rate of efflux of Rb from frog skeletal 
muscle caused by compound 48/80. This result was simi-
lar to that seen in Chapter II for P815 cells challenged 
with compound 48/80. (Figure 5) Figure 19 shows the 
86 + dependence in the Rb -efflux in the frog sartorius 
muscle as a function of concentration of 48/80 and as 
a function of the time during which the muscle was 
exposed to the agent. At all doses of compound 48/80 the 
rate of 86Rb+-efflux was fairly constant during the 62 
minutes in which samples were taken. 
Figure 20 shows the effect of verapamil on 86Rb+-
efflux in frog skeletal muscle challenged with verapamil. 
The verapamil at low concentrations (< 400 µg/ml) caused 
86 + 
an inhibition of the spontaneous release of Rb from 
the muscle while at higher concentrations the drug causes 
86 + 
an increase in the Rb -efflux from the muscle. This 
result is very similar to that in Chapter II obtained 
for 86Rb+-efflux from rat mast cells loaded with 86Rb+-
3H-serotonin and challenged by verapamil. 
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Figure 18 
Initial rates of 86Rb+-efflux from frog skeletal 
muscle challenged with compound 48/80. The 
muscles were preincubated in 10 µCi/ml of ~6RbCl 
in PAB at 25°C for 1.5 hours. The muscles were 
prepared for pharmacological challenge by 
sequential incubation in two 5 ml volumes of PAB. 
Prior to each 10 minute incubation the muscles 
were dipped in a large volume of PAB. After prepara-
tion, the muscles were challenged with compound 48/80 
for 10 minutes. Aliquots of the extramuscular 
buff er were sampled and counted by the usual methods 
of scintillation counting. The rates are expressed 
in cpm/mg per min. The muscles used were the 
semimembranosus C-• - •- • - ) and the sartorius 
(-•-•-•-•-•-). The estimated error was + 5%. 
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Figure 19 
Efflux of 86Rb+ from a frog sartorius muscle 
challenged with compound 48/80 for different 
periods of time. The details of this experiment 
are described in Figure 18. The curves represent 
a direct count of an aliquot of the buffer con-
taining the sartorius divided by the muscle mass. 
The aliquots were sampled at 10 minutes (lower-
most curve), 37 minutes (middle curve) and 62 
minutes (uppermost curve). The estimated error 
for this experiment was 50 cpm/mg. 
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Figure 20 
Initial rates of 86Rb+-efflux from frog skeletal 
muscle challenged with verapamil. Details of 
the experimental procedure are described in 
Figure 18. Semitendinosus muscle (---0---0---0---) 
and muscles of the shin complex (-•-•-•-) were 
challenged by the drug for 10 minutes at 25°C. 
86Rb+-efflux was expressed in units of cpm/mg 
per min. The estimated error was 5%. 
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Protein Degradation in Skeletal Muscle 
Compound 48/80 (2 mg/ml) caused a large increase in 
the rate of protein degradation in frog skeletal muscles 
relative to controls (Figure 21). Protein degradation 
was estimated to be a function of release of free tyro-
sine into the medium and into the internal pools of the 
muscle. This amino acid was chosen because it is not 
metabolized and does not itself alter the rates of protein 
synthesis or degradation (Kameyama and Etlinger, 1979, 
Fulks et al, 1975). This effect was relatively fast because 
significant differences in the tyrosine levels released 
into the extracellular pool could be detected in the 
first 15 minutes after challenge by the drug. The approxi-
mately 2-fold increase in net protein degradation was 
correlated with the characteristic contracture of the 
muscle caused by compound 48/80. 
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Figure 21 shows the effect of compound 48/80 on 
protein degradation in frog skeletal muscle. The re-
sults are pooled for four quartets of muscles; the 
sartorius, the semitendinosus, the gracilis major and 
the so-called shin complex. The statistical analysis 
using the t-test for paired observations (Sokal and 
Rohlf, 1969) is summarized in the following Table: 
control vs 48/80 (2 mg/ml) 
control vs neuraminidase 
neuraminidase vs 
neuraminidase then 48/80 
significant (P < 0.05) 
not significant 
not significant 
The results of a preliminary experiment on protein 
degradation were very similar to Figure 12 and are sum-
marized in the following Table: 
Treatment 
control (normalized) 
compound 48/80 (2 mg/ml) 
neuraminidase 
neuraminidase then 
compound 48/80 
Relative Degradation Rate 
100% 
296% 
139% 
108% 
In all experiments involving protein degradation only the 
muscles challenged with 6ompound 48/80 and not pretreated 
with neuraminidase showed a contracture. 
Figure22 shows that compound 48/80 caused a dose-
dependent increase in protein degradation in LS myoblast 
cells. 
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Figure 21 
Protein degradation in frog skeletal muscle : 
effect of neuraminidase and compound 48/80. This 
histogram summarizes the pooled results derived 
from four quartets of muscles in one controlled 
experiment. The muscles used were the sartorius, 
semitendinosus, gracilis major and the shin complex. 
The control values were normalized within the 
quartets and a ratio determined for values of the 
muscles treated with neuraminidase and/or c~mpound 
48/80 (2 mg/ml). The error bars on the treated 
muscles represent the standard deviation of these 
ratios of treatments to controls. The standard 
deviation of the control values before normaliza-
tion was 78 + 12 pmoles Tyr/mg per hr. 
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Figure 22 
Effect of compound 48/80: protein degradation in 
L8 myoblast cells. The L8 myoblast cells were 
challenged with compound 48/80 for one hour at 37°C. 
Total protein degradation was measured as the sum 
of the tyrosine released into the extracellular 
buffer and the free tyrosine in the intracellular 
pools. The units were nmoles Tyr/106 cells. The 
details of the method for measuring protein degradation 
in tissue culture cells are described in Materials 
and Methods, Chapter IV). 
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Uptake of 45ca in Skeletal Muscles 
Compound 48/80, at concentrations sufficient to cause 
an observable contracture, also caused a significant 
45 increase in Ca-uptake into frog skeletal muscle. In 
four distinct experiments involving seven muscle pairs, 
compound 48/80 (2 mg/ml) caused a (2.2 ! 0.5)-fold increase 
over controls in initial 45ca-uptake. Neuraminidase pre-
treatment of the muscles did not abolish this effect. 
For example, three muscle pairs, pretreated with neuraminidase 
then challenged with compound 48/80 (2 mg/ml) showed a 
(2.2 ! 0.6)-fold increase over muscles only treated with 
neuraminidase in initial 45ca-uptake. 
Figure 23 shows that neuraminidase-treated muscles 
45 have a higher rate of Ca-uptake relative to non-treated 
muscles. The results from another•pair of muscles were 
pooled with the two pairs of muscles in Figure 21 for a 
test of statistical significance. Using a t-test for 
paired comparisons (Sokal and Rohlf, 1969) the difference 
between 45ca-uptake in muscles treated with neuraminidase 
and control muscles was found to be statistically 
significant (P < 0.05). 
The measured 1145ca-uptake" represents the amount of 
label that has been taken up during the exposure of the 
muscle to the 45ca and then retained by the muscle until 
completion of a workup consisting of four washes over a 
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period of approximately 1.5 hours. The purpose of these 
washings is to exchange membrane-bound 45ca with cold 
calcium. Since some intracellular 45ca could exchange 
with calcium in the extracellular medium during the 
workups, the measured 45ca retained in the muscle -need not 
represent total uptake of 45ca during the pharmacological 
challenge but instead represents the difference between 
the 45ca gained during exposure of the muscle to 45ca 
during the incubation with drug and the subsequent loss 
of the 45ca during the workup of the muscle. Indeed, 
calcium exchange does occur in frog sartorius muscle 
when exposed to frog Ringer's solution. For example, 
Cosmos and Harris (1961) found that in muscle incubation 
in frog Ringer's there was a steady net inflow of Ca++; 
yet there was some exchange of label indicating an efflux 
of 45ca out of the muscle. 
Assuming that a gram of muscle equals a milliliter 
of myoplasm, the increase in 45ca-uptake caused by 
compound 48/80 translates to a rate of increase in 
myoplasmic [Ca++] of rv 3 µM per minute if the "influx" 
of calcium calculated from 45ca-uptake was totally 
directed into the myoplasm with no uptake by other intra-
cellular calcium pools. 
Figure 23 shows that verapamil inhibits the uptake 
of 45ca caused by compound 48/80. Interestingly, vera-
pamil, alone, causes a contracture and seems moreover 
to enhance the contracture caused by compound 48/80. 
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Figure 23 
Calcium uptake in frog skeletal muscle: effect 
of neuramindase _ and compound 48/80. Figure 
shows the results of a representative experi-
ment derived from two quartets of frog skeletal 
muscle. The muscles were incubated in PAB 
at 37oc with 45ca at a specific activity of 
0.724 pmole/cpm. The challenge by 48/80 was 
for 12 minutes. The neuramindase pretreatment 
was ~ 85 minutes at 0.25 units/ml. The key 
observation was that only the muscles challenged 
by compound 48/80 (2 mg/ml) showed the character-
istic contracture. The control muscles, muscles 
pretreated with neuramindase, and muscles pre-
treated with neuramindase and subsequently chal-
lenged by compound 48/80 were uniformly flaccid. 
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Figure 24 
Effect of verapamil and compound 48/80 on calcium 
uptake in frog skeletal muscle. The histogram 
represents an experiment involving a 
quartet of frog semimembranosus muscles. 
The challenge by the various drugs was for five 
minutes with the verapamil and compound 48/80 
being added simultaneously to the one muscle. 
The control muscles did not show any observable 
contracture. Muscles treated only with verapamil 
or compound 48/80 showed an observable contracture. 
The muscle treated with both drugs simultaneously 
was observed to have a "stronger" contracture than 
muscle treated with only compound 48/80 or only 
verapamil. The estimated error was + 3 pmoles/mg. 
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Protein Synthesis in Skeletal Muscle 
Figure 25 shows the effect of compound 48/80 on the 
rate of protein synthesis in frog skeletal muscle. In 
these experiments only muscles challenged with compound 
48/80 and not pretreated with neuraminidase showed an 
observable contracture. A statistical analysis of 
the results of two experiments examining protein synthesis 
in frog skeletal muscle indicated no significant difference 
in the rate of protein synthesis between any two of the 
experimental treatments. The statistical test used 
was a t-test comparison for paired values (Sokal and 
Rohlf, 1973). 
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Figure 25 
Protein synthesis in frog skeletal muscles: 
effect of neuraminidaseand compound 48/80. 
This histogram summarizes the results from five 
quartets of muscles in two separate experiments. 
The control muscles were normalized to the 100% 
level of tyrosine incorporation. Examples of the 
incorporation of tyrosine into control muscles are: 
semitendinosus 7.0 pmole Tyr/mg per hr 
sartorius 7.8 pmole Tyr/mg per hr 
gracilis major 18.5 pmole Tyr/mg per hr 
semimembranosus 15.9 pmole Tyr/mg per fir 
The incorporation of Tyr into muscles pretreated 
with neuroaminidase and/or challenged with 2 mg/ml 
compound 48/80 was divided by the control values. 
A standard deviation of these ratios for each group 
was calculated and is represented by the error bars 
on the histogram. 
Normalized 
muscles 
Compound 48/80 
Pretreatment 
Neuraminidase 
Pretreatment 
Neuramindase 
0 
% Tyrosine Incorporation Relative to Control 
._.., f-1 ~ ~ m oo o ~ 
0 0 0 0 0 0 
I ··~~~~~~~~~~~.-~~~~--.-~~~~--:ii------------------
• . 
' 
I 
.. 
' 
then Compound 48/80L-~~~~~~~~~~~~~~~~~~~--------1 
t--i 
l..11 
N 
153 
DISCUSSION 
Model for the Contracture of Frog Skeletal Muscle Caused 
by Compound 48/80 
In order to simplify the following, the discussion 
begins with the presentation of a hypothetical model for 
the mechanism by which pharmacological agents such as 
compound 48/80 interact with muscles and thereby cause 
effects such as contracture. Subsequently, the results 
obtained in these studies, and of others, will be discussed 
in terms of this postulate. 
The model features two, unconnected processes which 
can be initiated by agents such as compound 48/80; 
++ (i) release of Ca from the sarcoplasmic reticulum into 
the myoplasm which causes the muscle to contract. (ii) 
an independent increase in the rate of Ca++ influx across 
the cell membrane. (This influx need not result in a 
net increase in [Ca++] in the myoplasm as the incoming 
calcium may be taken up by the sarcoplasmic reticulum 
and/or pumped back out of the cell as rapidly as it 
enters.) 
The mechanistic pathway of the contractures caused 
by compound 48/80 is initiated by the binding of the 
drug to a surface molecule situated on the membrane of the 
t-tubule; this surf ace molecule includes sialic acid 
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residues which must be intact for interaction with compound 
48/80. The interaction of compound 48/80 with a surface 
molecule in the t-tubules transmits a "signal" to a region of 
the membrane of the sarcoplasmic reticulum which is essentially 
in contact with the membrane of the t-tubule; this causes a sharp 
increase in the calcium permeability across the membrane 
of the sarcoplasmic reticulum such that large amounts of 
calcium flow out of this organelle into the surrounding 
myoplasm. (The nature of the "signal" is not known but 
could be an important component of the coupling of 
excitation to contraction in skeletal muscle. Chapter I). 
This increase in myoplasmic [Ca++] in turn activates 
the contractile apparatus causing the muscle to contract. 
Moreover, the increase in myoplasmic [Ca++] activates 
calcium-dependent protein degradation in the muscle and 
also causes an increase in K+ permeability of the outer 
membranes of the muscle. 
In a separate process, compound 48/80 causes an influx 
of extracellular Ca++ across those regions of the muscle 
membrane not in direct contact with the terminal cisternae 
of the SR. This entering Ca++ can be rapidly taken up 
by the intracellular calcium pools, mainly the sarcoplasmic 
reticulum. As noted earlier, the sarcoplasmic reticulum 
has the ability to remove very rapidly calcium 
from the myoplasm by virtue of the high rate and capacity 
of its ATP-dependent Ca++ pumps; indeed, such removal of 
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calcium from the myoplasm by the sarcoplasmic reticulum 
leads in normal circumstances to the rapid relaxation of 
a contracted muscle. 
If compound 48/80 does not interact with the t-tubular 
"trigger" structures but can still cause the influx of 
++ ++ 
extracellular Ca across the muscle membrane, Ca 
pumping capacity of the SR may well be sufficient to pre-
. [Ca++] f vent the myoplasm1c rom reaching the threshold 
required for contractures. Thus one may observe an uptake 
of Ca++ without concomitant contraction. However, when 
compound 48/80 also activates the "trigger" structures 
causing release of Ca++ from the SR and also allows the 
concentration of myoplasmic [Ca++] to reach the threshold 
required for contraction. (The amount of calcium released 
in this way from the sarcoplasmic reticulum greatly 
++ 
exceeds the capacity of any ATP-dependent Ca pumps 
++ to remove Ca from the myoplasm.) 
Figure 26 is a schematic diagram of skeletal muscle 
illustrating the structures of skeletal muscle relevant 
to the proposed model. 
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Figure 26 - Schematic of Skeletal Muscle 
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Evidence Relevant to Location of "Trigger" Structures in 
t-Tubules 
The contracture of frog skeletal muscle caused by 
compound 48/80 is inhibited by pretreatment of the muscle 
with neuraminidase (Figures 2land 25). Neuraminidase 
does not penetrate the plasma membrane (Gottschalk, 
1972), thus the target molecule for compound 48/80 
that "triggers" the contracture should reside on the 
surface of . the muscle and its activity should depend 
on sialic acid residues susceptible to removal by 
neuraminidase. 
In this regard, Dorrscheit-Kafer (1977) found that 
pretreatment of frog sartorii with neuraminidase caused 
the threshold membrane potential for contraction to be 
raised and found that increases in extracellular Ca++, 
an ion that preferentially binds to sialic acids over 
other physiological ions (Jaques et al, 1977),also 
raised the contraction threshold. This finding indicated 
that a cell surface structure which required sialic 
acids for maximal activity was involved in excitation-
contraction coupling in skeletal muscles. This molecule 
and the neuraminidase-sensitive "trigger" molecule of 
our model may well be identical. 
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The model proposes that the interaction of compound 
48/80 occurs with the "trigger" structure located on the 
surface of the t-tubules. In this regard, the study of 
glycerol-treated muscles demonstrated that the t-tubules 
were essential for excitation-contraction coupling. 
Micrographs indicate that glycerol treatment causes a 
reorganization of the t-tubules in such a way that they no 
longer appear as the intermediate element of the triad 
of the SR, t-tubule and the sarcolernma and seem physically 
pinched off from the sarcolernma (Howell and Jenlon 
1967). Muscles treated in this way with glycerol 
quickly loose their twitch response and their ability 
to contract in 35 mM K+ Ringers but still respond to 
caffeine, a direct activator of the SR. These observations 
indicate that the coupling between the muscle action 
potential and the SR has been disrupted by the glycerol treatment, 
Morphologically, the t-tubules lie is close proximity 
to the terminal cisternae of the SR and approximately 
80% of the surf ace area of the t-tubules about the 
terminal cisternae (Peachey, 1965). 
Compound 48/80 likely causes the activation of Ca++ 
release from the sarcoplasmic reticulum by a process 
which depends on receptors which contain sialic acid 
residues and which are localized in the t-tubules. 
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Similarly, normal excitation-contraction depends on a 
coupling process localized in the t-tubules and dependent 
on sialic acid susceptible to neuraminidase (Dorrsheidt-
Kafer, 1977). These similarities lead to the suggestion 
in the model that the cell surface molecules involved 
in these two processes are the same. 
Incidentally, both compound 48/80 (MW 800) and V. 
Cholerae neuraminidase (MW 90,000) should be able to enter 
the lumen of the t-tubules as even larger molecules 
such as ferritin (MW 460,000) and peroxidase (MW 200,000) 
can easily enter these regions (Constantin, 1975). 
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Evidence for an Increase in Myoplasmic [Ca++] 
A central feature of the model for contracture caused 
by compound 48/80 is that in normal muscle the drug 
triggers a process that leads to an increase in myoplasmic 
[Ca++]. Likewise, the normal excitation-contraction 
cycle of skeletal muscle features a transient increase 
in myoplasmic [Ca++] from 0.1 µM to approximately 2 µM 
(Caputo, 197m with the source of this increase being 
the sarcoplasmic reticulum (Hasselbach, 1980). Therefore, 
we will examine the evidence that compound 48/80 does 
indeed cause an increase in myoplasmic [Ca++]. 
1) 86Rb+-Efflux 
Compound 48/80 causes a dose-dependent increae 
in the efflux of 86 Rb+ from frog skeletal muscle (Figure l~. 
In non-excilatory cells, K+-efflux (Rb+ is an analogue of 
K+) is correlated with an increase in the cytosolic con-
centration of Ca++. This increase in the cytosolic 
[Ca++] is believed to increase the permeability of K+ 
across the plasma membrane which causes the K+ to flow 
out of the cell down it concentration gradient (Putney, 
1979). If one extends this hypothesis to skeletal muscle, 
the increase in the 86Rb+-efflux caused by compound 48/80 
suggests an increase in the myoplasmic [Ca++]. 
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2) Protein Degradation 
Further evidence that contracture of frog skeletal 
muscle caused by compound 48/80 features an increase in 
myoplasmic [Ca++] was derived from studies of protein 
degradation in the muscles. We will briefly discuss 
the results and than will review the findings of others 
that show the rate of intracellular proton degradation 
reflects cytosolic [Ca++]. 
Figure 21 shows a significant increase in the rate 
of protein degradation in muscles challenged with com-
pound 48/80 relative to control muscles. This increase 
in the rate of protein degradation correlates with the 
observable contracture of frog skeletal muscle caused 
by compound 48/80. In contrast, there was no significant 
increase in the rate of protein degradation in muscles 
pretreated with neuraminidase and subsequently challenged 
with compound 48/80 relative to control muscles pre-
treated with neuraminidase but then not challenged 
with compound 48/80 (Figure 21). Pretreatment of the 
muscle with neuraminidase also abolishes the contracture 
caused by compound 48/80 further implying that increase 
in the rate of protein degradation may correlate with 
contracture of the muscle. Further evidence along these 
lines is provided by our finding that a significant 
dose-dependent increase in the rate of protein degradation 
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was seen in L8 myoblast cells treated with compound 48/80 
(Figure 22). 
We suggest that during contracture the relative in-
crease in the rate of protein degradation was due to 
. . h . . [C ++] an increase in t e concentration of myoplasmic a . 
This correlation has been previously proposed by others. 
Kameyama and Etlinger (1979) showed that the rate of protein 
degradation in rat soleus muscles in the presence of 
++ 
extracellular Ca was increased when the muscles were 
exposed to the calcium ionophore, A23187 relative to 
controls in the same medium but not treated with the 
ionophore. Cochrane and Douglas (1973) demonstrated 
that mast cells in the presence of extracellular Ca++, 
and treated with A23187 underwent degranulation, a process 
likewise thought to reflect on an increase in cytosolic 
++ [Ca ] (Chapter II, Theoharides and Douglas, 1978). 
Therefore, if A23187 treatment of mast cells and rat 
soleus muscle effects intracellular [Ca++] in the same 
manner, then rat soleus muscles should experience an in-
crease in myoplasmic [Ca++] on treatment with A23187 and 
such an increase in [Ca++] would lead to an increase in 
protein degradation. 
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There is circumstantial biochemical evidence showing 
that protein degradation in skeletal muscle depends on 
the intracellular concentrations of calcium. For 
example, Reddy et al (1975) and Kar and Pearson (1978) 
have isolated neutral proteases that are activated by 
Ca++ and hydrolyze a variety of muscle proteins. More-
over, Dayton et al (1976) have purified a Ca++_activated 
protease, possibly involved inmyofubrillarprotein turn-
over, from porcine skeletal muscle. 
3) Summary 
In summary, the increase in protein degradation 
which correlates with contracture caused by compound 
48/80 (Figure 21) and the increase in the efflux of 
86Rb+ (Figure 18) which depends on the dose of compound 
48/80 suggest that an increase in the concentration 
++ 
of myoplasmic [Ca ] may be the central feature of the 
mechanism of contracture in frog skeletal muscle caused 
by challenges with compound 48/80. 
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Possible Source of Ca++ for Contracture 
In our proposed model for contracture caused by com-
pound 48/80, there are two independent processes that 
could effect the concentration of myoplasmic [Ca++]: 
an increase in the rate of Ca++ influx across the cell 
++ 
membrane and/or the net release of Ca from the SR. 
Experimental evidence suggests that extracellular calcium 
is not sufficient to cause contracture of frog skeletal 
muscle challenged with compound 48/80. Accordingly, 
the sarcoplasmic reticulum seems the most likely source 
of calcium required for contraction. 
1) Extracellular Calcium 
Evidence that extracellular calcium is not the 
source includes the following observation. Compound 
48/80 could cause a contracture of isolated frog skeletal 
muscle incubated in physiological buffer containing no 
calcium. This contracture was similar to a normal 
contracture casued by the drug in the presence of the 
++ 
regular 1.8 mM Ca physiological buffer. This observed 
independence of the contracture on extracellular calcium 
is similar to the lack of a requirement for extracellular 
calcium in the degranulation of mast cells caused by 
compound 48/80 (Uvnas and Thon, 1961),we have also dis-
cussed (Chapter III) 
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a) Measurement of Ca-uptake - The uptake of extracellular 
calcium by muscles challenged with compound 48/80was increased 
relative to control muscles; however this increase was not cor-
related with a contracture of the muscle (Figure 23). 
Specifically challenge with compound 48/80 of muscles 
pretreated with neuraminidase causes the same relative 
increase in 45ca uptake as does challenge with compound 
48/80 of muscles not treated with the enzyme; these 
muscles however did not undergo a contacture. 
The model asserts that compound 48/80 causes an increase 
in the influx across the sarcolemma of extracellular 
calcium; this process leads to an increased uptake of 
45 · . 1 . [Ca++], Ca without, necessarily an 1ncrease.1nmyop asm1c 
because the ATP-dependent pumps of the SR take up the 
45
ca upon entry into the myoplasm and prevent its 
exchange with the extracellular medium. When the SR is 
not activated by compound 48/80 because of neuraminidase 
pretreatment of the muscle, the influx of extracellular 
calcium caused by compound 48/80 is not sufficient to 
activate the contractile apparatus because the SR takes up 
the entering Ca++ sufficiently rapidly to not increase the 
myoplasmic [Ca++] enough to cause the muscle to contract. 
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b) Effect of Verapamil - Verapamil caused a decrease 
in the uptake of 45ca in frog skeletal muscles simultan-
eously challenged with compound 48/80 relative to muscles 
only treated with 48/80 but does not inhibit the con-
tracture (Figure 24). In fact, the two drugs where added 
simultaneously to a muscle seen to cause a "stronger" 
contracture than either did alone. Verapamil blocks 
the influx of calcium across the plasma membrane in a 
variety of preparations of smooth and cardiac muscle 
(Fleckenstein, 1977). If this mechanism of action could 
be extended to skeletal muscle, then the results of 
Figure 24 are readily explained; the drug inhibited the 
increase in uptake of 45ca caused by compound 48/80 
by specifically blocking the influx of extracellular 
calcium in the muscle. Since this blockage by verapamil 
of the influx of extracellular calcium does not inhibit 
contracture caused by compound 48/80, we conclude that 
an increase in uptake of extracellular calcium does not 
correlate with contracture of the muscle. According to 
our model, this suggests that verapamil blocks calcium 
influx across the sarcolemma but does not interfere with 
the operation of the receptors in the t-tubules which 
on binding of compound 48/80 mediate the contracture. 
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Interestingly, verapamil, alone, causes a contracture 
of frog skeletal muscle. This is a surprising result for 
verapamil has been defined as a specific blocker of 
calcium channels of the plasma membrane of a number of 
cells and tissues (Fleckenstein, 1977) but the contraction 
of muscle depends on the mobilization of Ca++ from the 
SR into the myoplasmic pool (Hasselbach, 1980) not calcium 
influx across the sarcolemma. Indeed, verapamil may 
be acting as a blocker of calcium channels when the drug 
at low concentrations causes a decrease in the spontaneous 
efflux of 86Rb+ from frog muscles (Figure 20). This 
decrease in 86Rb+-efflux could be reflective of a decrease 
in myoplasmic [Ca++] (see Chapter II, Putney (1979)) . 
caused by verapamil blocking the spontaneous flux of Ca++ 
into the myoplasm from membrane bound pools and/or the 
extracellular medium. However, at higher concentrations 
of verapamil this effect due to the blockage of calcium 
channels is overcome and there is an increase in myoplasmic 
·[ca++] which leads to observed increases in 86Rb+-efflux 
and to the observed contracture. In this case, the 
mechanism of contracture of skeletal muscle caused by 
verapamil is unknown but may be related to the mechanism 
of degranulation of mast cells caused by the drug 
(Chapter III) in verapamil is proposed to act only after 
entry into the cell. 
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c) Summary - In summary, we have examined several 
lines of experimental evidence and made an analogy to 
mast cells to propose that in skeletal muscle the increase 
in calcium influx from the extracellular environment 
caused by compound 48/80 is neither a sufficient condition 
nor a necessary condition for contracture. Accordingly, 
the extracellular pool does not seem to be a likely 
++ 
source of Ca that causes the increase in myoplasmic 
[ca++] b 1 and su sequent y causes contracture. 
45 The mechanism of the increased uptake of Ca caused 
by compound 48/80 probably depends on a membrane compon-
ent which interacts with compound 48/80 to increase the rate 
of influx of calcium into the muscle. The function of this 
component of the sarolemma is not affected by treat-
ment of the muscle with neuraminidase and the influx of 45ca 
is taken up by an intracellular calcium pool, presumably, 
the sarcoplasmic reticulum. 
2) Sarcoplasmic Reticulum 
Possible indirect evidence that the sarcoplasmic 
reticulum is the source of Ca++ required for the contrac-
ture of muscle caused by compound 48/80 is that contrac-
ture caused by high concentrations of caffeine is generally 
similar in appearance ie shortened muscle and loss of 
plasticity (Schwarz et at, 1978). Moreover, caffeine 
contracture is caused by the direct interaction of the 
++ . drug with the SR causing the release of Ca into the 
myoplasm (Weber and Herz, 1968). 
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Conclusion and Further Tests of the Model 
The contracture of skeletal muscle challenged with 
compound 48/80 correlates with an increase in the rate 
86 + 
of protein degradation and the rate of Rb -efflux 
in the muscle; these observations suggest an increase 
in myoplasmic [Ca++]. Compound 48/80 also caused an 
45 increase in the uptake of Ca, however this increase 
does not correlate with contracture. Pretreatment 
with neuraminidase of the muscles abolished the contrac-
ture indicating that compound 48/80 interacts with a 
"trigger" structure that contains sialic acid residues 
essential for activity, such pretreatment does not how-
ever effect the increase in rate of influx of Ca++ in re-
sponse to compound 48/80. 
The model proposes that the "trigger" structure is 
located on the t-tubular membrane proximate to the 
terminal cisternae of the sarcoplasmic reticulum. 
Thus a test of the model would involve treatment of the 
muscle with glycerol causing a separation of the t-tubules 
from the sarcolemma and subsequent challenge with compound 
48/80. If the contracture does not occur under these 
conditions the site of the ''trigger'' structure would 
likely be in the t-tubules. As a positive control, 
caffeine should still be able to cause a contracture under 
these conditions otherwise the glycerol treatment would 
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also be affecting the function of the SR. (Note, 
glycerol-~reatedmuscles are still activated by caffeine, 
Howell and Jenlon, 1967). 
The increase in 86Rb+-efflux caused by compound 48/80 
implies that there was also an increase in myoplasmic 
++ [Ca ]. The question is whether the increase in 
myoplasmic [Ca++] was directly the result of the inter-
action of compound 48/80 with the "trigger" structure 
proposed in the model. If pretreatment of the muscle 
with neuraminidase lowers the increase of 86Rb+-efflux 
caused by 48/80 then one would conclude that the "trigger" 
structure sensitive to neuraminidase is indeed important 
. . [Ca++] . 86 + in controlling myoplasmic If, however, Rb -
efflux caused by compound 48/80 is not affected by 
neuraminidase then the model is not valid unless other 
factors besides the release of calcium from the SR into 
the myoplasm can influence 86Rb+-efflux. For example, 
the K+( 86Rb+) channels could "sense" the increased influx 
of Ca++ across the muscle membrane seen in muscles 
pretreated with neuraminidase and challenged with compound 
48/80. Furthermore, neuraminidase itself causes an 
45 increase in Ca uptake in skeletal muscle (Figure 23 and 
similarly in cultured heart cells (Langer et al, 1976) 
Again, this increased influx of Ca++ across the muscle 
( d . 1 . [Ca++] l membrane as istinct from increased myop asmic 
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caused by neuraminidase could be "sensed" by the K+ 
( 86Rb+) channels thus causing an increase in 86Rb+-
efflux such that the experiment would not reveal any 
change in myoplasmic [Ca++] caused by compound 48/80. 
The existence of a highly specialized organelle, 
such as the sarcoplasmic reticulum, for the generation 
and removal of transient increases in cytosolic [Ca++] 
has not been demonstrated in mast cells, nevertheless compound 
48/80 causes the degranulation of mast cells presumably 
by mobilizing an intracellular pool of calcium (see 
Chapter II). An experiment examining the effect of 
neuraminidase treatment on uptake of 45ca into mast 
cells challenged with compound 48/80 could show a result 
similar to skeletal muscle (Figure23); neuraminidase 
treatment of mast cells inhibits degranulation but 
does not change the increase in 45ca-uptake caused by 
challenge with compound 48/80. Using our model for 
skeletal muscle, such a result would indicate that the 
activation of an intracellular calcium pool in the mast 
cell was dependent on the close proximity of the pool 
to neuraminidase-sensitive "trigger" structures of the plasma 
membrane and the increase in 45ca-uptake was due to ATP-dependent 
calcium pumps on an intracellular pool rapidly taking 
up the increase in the influx of extracellular Ca++ and 
preventing the cytosolic [Ca++] from reaching the 
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threshold for degranulation. This finding would suggest 
that the functional internal structure .. of the mast cell . 
is complex and similar to skeletal muscle. However, 
influx of extracellular Ca++ caused by crosslinking of 
receptors to IgE is sufficient and necessary to cause 
degranulation of mast cells (Hirata and Axelrod, 1980) 
indicating that this, possibly large, influx of Ca++ 
++ is not prevented from increasing cytosolic\ [Ca ]to the 
threshold for degranulation by bein~ caken up by an intra-
cellular calcium pool analagous to the SR in skeletal 
muscle. 
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Parallels Between Pharmacological Challenge of Rat Mast 
Cells and Skeletal Muscle. A Summary 
Table IV lists the findings of this thesis on rat 
mast cells and frog skeletal muscle that are similar for 
both tissues. 
These similar findings indicate that certain steps 
of the mechanistic pathway of siimulus-secretion coupling 
in mast cells might be analogous to steps in the coupling 
of pharmacological stimulus to contracture or even to 
excitation-contraction coupling in skeletal muscle. 
Such steps include the binding of compound 48/80 to 
receptors of the cell surface which have sialic acid 
residues. This in turn causes the mobilization of calcium 
from intracellular pools into the cytosol consequently 
activating the function characteristic of the tissue; 
degranulation of mast cells and activation of the con-
tractile apparatus in skeletal muscle. 
Interestingly, mast cells also contain a "contractile 
apparatus'' composed of actin microfilaments, that have 
been proposed upon activation to eject the granules from 
exocytotic pits at the cell surface (Cochrane and Douglas, 
1974). 
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Table IV, Chapter IV - Summary of Similar Findings on Rat Mast 
Cells and Frog Skeletal Muscle of this Thesis 
Similar Findings 
1. compound 48/80 causes 
an increase in 86Rb+-efflux 
2. no absolute requirement 
++ for extracellular Ca 
3. low doses of verapamil 
inhibit spontaneous 
release of 86Rb+ 
4. high doses of verapamil 
caused increase re-
86Rb+ d . lease of an acti-
vat ion 
5. processes of activation 
are neuraminidase-
sensitive 
Implication 
. . l" [Ca++] increase in cytoso ic 
. f f c ++ . h . in lux o a into t e tissue 
not required for activation 
verapamil inhibits mobilization 
++ 
of Ca at those concentra-
tions 
verapamil overcomes the 
inhibition of mobilization of 
Ca++ and itself causes mobiliza-
tion of Ca++ 
the target of compound 48/80 
contains essential sialic 
acid. 
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